Tetralogy of Fallot

Complex MONDO:0008542 Pathograph 18 Show in embeddings browser conotruncal heart defect cyanotic congenital heart disease

The most common cyanotic congenital heart disease. The name is a historical accident that obscures the mechanism: the four cardinal features are not four defects but four consequences of one, namely anterocephalad deviation of the outlet septum during outflow tract septation. A septum that deviates cannot close the interventricular communication, cannot leave the aorta aligned over the left ventricle, and cannot leave the subpulmonary infundibulum a normal calibre, and the right ventricle then hypertrophies against the resulting load. Everything clinically important follows from the severity of that last obstruction, which determines whether blood shunts left to right or right to left, and therefore whether the child is pink or blue.

Ask OpenScientist

Ask a research question about Tetralogy of Fallot. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
9
Pathophys.
12
Phenotypes
2
Gaps
18
Pathograph
5
Genes
7
Medical Actions
3
Differentials
1
Models
1
Deep Research
🏷

Classifications

Harrison's Part
CARDIOVASCULAR
👪

Inheritance

1
Non-Mendelian with a Mendelian minority HP:0001426
Most cases are sporadic and multifactorial. A substantial minority, around eighteen percent in a comprehensively investigated cohort, carry an identifiable chromosomal or single-gene cause, the most common being the 22q11.2 deletion. The practical consequence is that genetic testing is worthwhile in every case despite most results being negative, because a positive result changes both extracardiac surveillance and recurrence counselling.
Non-Mendelian inheritance
Show evidence (1 reference)
PMID:19948535 SUPPORT Human Clinical
"Pathogenic genetic aberrations were found in 42 patients (18%)"
Quantifies the identifiable-cause fraction, which is what establishes that the majority is not Mendelian while a meaningful minority is.
?

Discussions and Knowledge Gaps

2
Should the four cardinal features be modelled as one lesion with four consequences, and does the eponym actively mislead?
OPEN QUESTION OPEN tetralogy_is_one_lesion_not_four
Attached to
pathophysiology#Anterocephalad deviation of the outlet septum pathophysiology#Second heart field and cardiac neural crest program disruption
The historical name enumerates four findings as though they were four defects, and generations of teaching have followed that enumeration. The embryological account is that a single anterocephalad deviation of the outlet septum produces all four as geometric consequences, and this entry models it that way, with one node for the deviation and separate downstream nodes for the septal defect, the obstruction, and the hypertrophy. The modelling choice is not merely tidy. It predicts that the features cannot be dissociated, which is what is observed, and it correctly identifies right ventricular hypertrophy as secondary and postnatal rather than congenital. It also makes the severity spectrum intelligible, since one deviation of varying degree explains a continuum from pink tetralogy to pulmonary atresia, whereas four independent defects would not. What remains genuinely open is whether the molecular lesions converge on septal position specifically or on outflow tract development broadly, with septal deviation being only one of several possible outcomes.
Proposed experiments
Quantitative morphometry of outlet septal position across genotype groups in fetal specimens
exp_tof_septal_position_quantification
Measure outlet septal deviation quantitatively across fetal specimens grouped by genotype, including 22q11.2 deleted, FLT4 or NOTCH1 variant, and genetically unexplained cases. If all genotypes converge on the same septal geometry, the single-lesion model holds across causes. If they differ systematically, the shared anatomy is a convergence point rather than the direct consequence of each lesion.
Show evidence (1 reference)
PMID:34905512 SUPPORT INDIRECT Human Clinical
"We discovered that the candidate gene expression was enriched in the myogenic progenitors of the cardiac outflow tract."
INDIRECT. Supports convergence of the genetic lesions on outflow tract development, which is the broader of the two readings; it does not establish that they converge on septal position specifically.
Given that transannular repair reliably produces lifelong pulmonary regurgitation, and that valve replacement has not been shown to reduce arrhythmia risk, when should the valve be replaced?
OPEN QUESTION OPEN the_repair_creates_the_next_disease
Attached to
pathophysiology#Postoperative pulmonary regurgitation and right ventricular remodelling pathophysiology#Ventricular arrhythmia and sudden death risk treatments#Pulmonary valve replacement after repair
This is the sharpest unresolved question in the modern management of this disease, and it exists because the operation succeeded. Relieving the outflow obstruction saved a generation of children and left them with an incompetent pulmonary valve, decades of right ventricular volume loading, and a late arrhythmic substrate. Valve replacement improves symptoms and is associated with lower observed ventricular tachycardia incidence, but current guidance declines to treat arrhythmia risk alone as an indication, because the evidence that replacement reduces subsequent arrhythmia is not robust. The clinician is therefore caught between operating early, committing a young patient to repeated prosthetic valve interventions over a lifetime, and operating late, by which point right ventricular remodelling may be irreversible. Resolving it requires knowing whether the fibrotic substrate regresses after unloading, which is a question about the biology of the remodelling node in this entry and not merely about trial design.
Proposed experiments
Serial cardiac magnetic resonance fibrosis mapping before and after pulmonary valve replacement stratified by preoperative right ventricular volume
exp_pvr_timing_substrate_regression
Follow patients undergoing pulmonary valve replacement with serial cardiac magnetic resonance fibrosis mapping and electrophysiological substrate assessment, stratified by preoperative right ventricular volume. The decision criterion is whether fibrotic burden regresses after unloading and whether that regression depends on operating before a volume threshold. A threshold effect would convert an open timing question into a measurable indication.
⚙

Pathophysiology

9
Second heart field and cardiac neural crest program disruption
A genetic lesion or teratogenic insult perturbs addition of second heart field progenitors to the developing outflow tract and migration of cardiac neural crest cells into it, during weeks three to eight of gestation. This is the same developmental program whose failure produces persistent truncus arteriosus, and the two diseases are best read as different severities and positions of failure in one process rather than as unrelated malformations.
migratory cardiac neural crest cell CL:2000073 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves migratory cardiac neural crest cell (CL:2000073). CL:2000073 is a cell type from the Cell Ontology. outflow tract myogenic progenitor CL:0000513 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves outflow tract myogenic progenitor, annotated with cardiac muscle myoblast (CL:0000513). CL:0000513 is a cell type from the Cell Ontology.
outflow tract morphogenesis GO:0003151 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased outflow tract morphogenesis (GO:0003151). GO:0003151 is a biological process from the Gene Ontology. ↓ DECREASED cardiac neural crest cell development GO:0061308 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased cardiac neural crest cell development, annotated with cardiac neural crest cell development involved in heart development (GO:0061308). GO:0061308 is a biological process from the Gene Ontology. ↓ DECREASED
outflow tract septum UBERON:0004142 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in outflow tract septum (UBERON:0004142). UBERON:0004142 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Hey2 mutant mouse OTHER Loss of a Notch pathway effector perturbs the developmental program of the outflow tract.
Downstream
Anterocephalad deviation of the outlet septum A disrupted progenitor and neural crest program produces a septum that forms in the wrong position rather than failing to form at all.
Show evidence (2 references)
PMID:34905512 SUPPORT Human Clinical
"We discovered that the candidate gene expression was enriched in the myogenic progenitors of the cardiac outflow tract."
Localises the genes carrying damaging de novo variants in this disease to the specific progenitor population of the outflow tract, which is the cellular claim this node makes.
PMID:34905512 SUPPORT Human Clinical
"To assess the impact of these mutations on early cardiac development, we integrated single-cell and spatial transcriptomics of early human heart development with our genetic findings."
States the method that joins the genetic findings to a developmental cell population, which is what makes the localisation more than an association.
Anterocephalad deviation of the outlet septum
The single anatomical lesion of this disease. The muscular outlet septum deviates anterocephalad relative to the muscular ventricular septum. Every one of the four cardinal features is a geometric consequence of that one deviation, which is why they occur together with essentially no exceptions and why the eponymous tetralogy is better understood as a monad.
outflow tract septum morphogenesis GO:0003148 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased outflow tract septum morphogenesis (GO:0003148). GO:0003148 is a biological process from the Gene Ontology. ↓ DECREASED
interventricular septum UBERON:0002094 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in interventricular septum (UBERON:0002094). UBERON:0002094 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Hey2 mutant mouse OTHER The mutant reproduces the malformation itself rather than an unrelated cardiac defect.
Downstream
Malalignment ventricular septal defect with overriding aorta A deviated septum cannot close the interventricular communication, and leaves the aortic root straddling it.
Right ventricular outflow tract obstruction The same deviation narrows the subpulmonary infundibulum.
Malalignment ventricular septal defect with overriding aorta
A large non-restrictive perimembranous defect, with the aortic valve annulus straddling it. Because the defect is non-restrictive, the two ventricles function as a single pumping chamber at systemic pressure, which is why the direction of shunting is decided entirely by the relative resistance of the two outflows rather than by the defect itself.
interventricular septum UBERON:0002094 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in interventricular septum (UBERON:0002094). UBERON:0002094 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Shunt direction determined by outflow resistance A non-restrictive communication allows flow to follow the path of least resistance.
Right ventricular outflow tract obstruction
Obstruction at infundibular, valvar, supravalvar, or branch pulmonary artery level, singly or in combination. The infundibular component is muscular and therefore dynamic, which is the mechanistic basis of the hypercyanotic spell and the reason severity can change from minute to minute in a way that fixed obstructions cannot.
pulmonary valve UBERON:0002146 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pulmonary valve (UBERON:0002146). UBERON:0002146 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Shunt direction determined by outflow resistance Obstruction to pulmonary outflow raises the resistance against which the right ventricle must eject, relative to the systemic circuit.
Right ventricular hypertrophy Chronic pressure loading of the right ventricle drives compensatory hypertrophy.
Shunt direction determined by outflow resistance
The pivot of the whole disease. With a non-restrictive ventricular septal defect, flow goes wherever resistance is lower. Mild outflow obstruction leaves pulmonary resistance below systemic and the shunt is left to right, producing the acyanotic or pink presentation. Severe obstruction reverses that and produces right to left shunting with cyanosis. This is also why raising systemic vascular resistance, which squatting does mechanically and phenylephrine does pharmacologically, terminates a hypercyanotic spell.
Downstream
Cyanosis and chronic hypoxaemia Right to left shunting delivers systemic venous blood to the aorta without pulmonary gas exchange.
Right ventricular hypertrophy
Secondary and largely postnatal, developing as the right ventricle ejects against systemic level pressure. It is the one cardinal feature that is a response rather than a malformation, which is why it is not present at the same severity from birth.
cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
cardiac muscle hypertrophy GO:0003300 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cardiac muscle hypertrophy (GO:0003300). GO:0003300 is a biological process from the Gene Ontology. ↑ INCREASED
Cyanosis and chronic hypoxaemia
Chronic arterial desaturation, with compensatory polycythaemia and, over years, digital clubbing. In the modern era of early repair these late consequences are increasingly historical in high-income settings and remain common where surgery is delayed.
Downstream
Postoperative pulmonary regurgitation and right ventricular remodelling Cyanosis is what forces early operation, and the operation itself creates the late lesion.
Postoperative pulmonary regurgitation and right ventricular remodelling
The defining problem of the adult with repaired tetralogy, and an iatrogenic one. Relieving the outflow obstruction, especially with a transannular patch, leaves the pulmonary valve incompetent. Decades of free pulmonary regurgitation then dilate the right ventricle, drive fibrosis, and build an arrhythmogenic substrate. The disease of the survivor is therefore not the disease that was repaired, which is the central fact of lifelong follow-up in this population.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Ventricular arrhythmia and sudden death risk Right ventricular dilation and fibrosis create the substrate for reentrant ventricular tachycardia.
Show evidence (1 reference)
PMID:39569497 SUPPORT Human Clinical
"Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot, precipitating a complex pathophysiological cascade that leads to increasing rates of morbidity and mortality with advancing age."
States that outflow dysfunction after repair is nearly universal and drives a cascade of rising morbidity and mortality with age, which is exactly the claim this node makes about the repair creating the next disease.
Ventricular arrhythmia and sudden death risk
The principal late cause of death after successful repair. It is deliberately not curated as conforming to cardiac_ion_channel_repolarization, because the substrate here is structural, consisting of surgical scar and fibrosis in a dilated ventricle, rather than a primary channelopathy in a structurally normal heart.
Show evidence (1 reference)
PMID:27329296 SUPPORT Human Clinical
"Chronic severe pulmonary regurgitation as a result of surgical repair can lead to myriad complications including right ventricular dysfunction, decreased exercise tolerance, right heart failure and symptomatic arrhythmias."
Attributes the late complications directly to the surgical repair, and names symptomatic arrhythmias among them, which is the specific claim this node makes.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Tetralogy of Fallot Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

12
Blood 1
Polycythaemia Polycythemia HP:0001901 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Polycythemia (HP:0001901). HP:0001901 is a phenotype from the Human Phenotype Ontology.
Cardiovascular 2
Ventricular septal defect OBLIGATE HP:0001629 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ventricular septal defect (HP:0001629). HP:0001629 is a phenotype from the Human Phenotype Ontology.
Right ventricular outflow tract obstruction OBLIGATE Pulmonic stenosis HP:0001642 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Pulmonic stenosis (HP:0001642). HP:0001642 is a phenotype from the Human Phenotype Ontology.
Integument 2
Cyanosis HP:0000961 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cyanosis (HP:0000961). HP:0000961 is a phenotype from the Human Phenotype Ontology.
Hypercyanotic spells Cyanosis HP:0000961 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypercyanotic spell, annotated with Cyanosis (HP:0000961), qualified as temporality recurrent. HP:0000961 is a phenotype from the Human Phenotype Ontology.
Temporal: RECURRENT
Growth 1
Failure to thrive HP:0001508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Failure to thrive (HP:0001508). HP:0001508 is a phenotype from the Human Phenotype Ontology.
Other 6
Overriding aorta OBLIGATE HP:0002623 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Overriding aorta (HP:0002623). HP:0002623 is a phenotype from the Human Phenotype Ontology.
Right ventricular hypertrophy OBLIGATE HP:0001667 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Right ventricular hypertrophy (HP:0001667). HP:0001667 is a phenotype from the Human Phenotype Ontology.
Heart murmur HP:0030148 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Heart murmur (HP:0030148). HP:0030148 is a phenotype from the Human Phenotype Ontology.
Digital clubbing Clubbing of fingers HP:0100759 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Clubbing of fingers (HP:0100759). HP:0100759 is a phenotype from the Human Phenotype Ontology.
Right aortic arch Right aortic arch with mirror image branching HP:0002627 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Right aortic arch with mirror image branching (HP:0002627). HP:0002627 is a phenotype from the Human Phenotype Ontology.
Anomalous coronary artery crossing the outflow tract Anomalous coronary artery arising from the opposite sinus HP:0025503 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anomalous coronary artery arising from the opposite sinus (HP:0025503). HP:0025503 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32156463 SUPPORT Human Clinical
"An anomalous coronary artery is reported in 2% to 23% of patients with tetralogy of Fallot (TOF). Knowledge of coronary anatomy prior to corrective surgery is vital to avoid damage to vessels crossing the right ventricular outflow tract (RVOT)."
Gives the reported prevalence range and states the surgical consequence, which is the reason this phenotype is curated at all. No frequency band is assigned because a range spanning 2 to 23 percent crosses the OCCASIONAL and FREQUENT boundaries and the meta-analysis is reporting heterogeneity rather than a point estimate.
🧬

Genetic Associations

5
22q11.2 deletion
Gene: TBX1 hgnc:11592 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TBX1 (hgnc:11592). hgnc:11592 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:19948535 SUPPORT Human Clinical
"Pathogenic genetic aberrations were found in 42 patients (18%), with 22q11.2 deletion as the most common diagnosis (7.4%), followed by trisomy 21 (5.2%) and other chromosomal aberrations or submicroscopic copy number changes (3%)."
Quantifies the deletion as the most common identifiable cause in an unselected cohort of 230 patients, with a counted denominator.
JAG1
Gene: JAG1 hgnc:6188 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is JAG1 (hgnc:6188). hgnc:6188 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:19948535 SUPPORT Human Clinical
"Mutations in JAG1 were detected in three patients with Alagille syndrome (1.3%), while NKX2.5 mutations were seen in two patients with non-syndromic ToF (0.9%)."
Quantifies the JAG1 and NKX2-5 contributions in the same cohort, with counted denominators.
NKX2-5
Gene: NKX2-5 hgnc:2488 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NKX2-5 (hgnc:2488). hgnc:2488 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:19948535 SUPPORT Human Clinical
"Mutations in JAG1 were detected in three patients with Alagille syndrome (1.3%), while NKX2.5 mutations were seen in two patients with non-syndromic ToF (0.9%)."
Quantifies the NKX2-5 contribution at 0.9 percent of an unselected cohort, which is what places it among the minor rather than major contributors.
FLT4
Gene: FLT4 hgnc:3767 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FLT4 (hgnc:3767). hgnc:3767 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:30582441 SUPPORT Human Clinical
"The NOTCH1 locus is the most frequent site of genetic variants predisposing to nonsyndromic TOF, followed by FLT4. Together, variants in these genes are found in almost 7% of TOF patients."
Ranks FLT4 as the second most frequent contributor after NOTCH1 and quantifies their combined yield at almost seven percent of patients, from a cohort of 829 undergoing whole exome sequencing.
NOTCH1
Gene: NOTCH1 hgnc:7881 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NOTCH1 (hgnc:7881). hgnc:7881 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (2 references)
PMID:30582441 SUPPORT Human Clinical
"The clustering of variants in 2 genes, NOTCH1 and FLT4, surpassed thresholds for genome-wide significance (assigned as P<5×10-8) after correction for multiple comparisons."
Establishes that only these two genes reached genome-wide significance in a cohort of 829, which is what separates them from the many candidate genes proposed for this disease.
PMID:30582441 SUPPORT Human Clinical
"Thirty-one changes were observed in 37 probands (4.5%; 95% CI, 3.2%-6.1%) and included 7 loss-of-function variants 22 missense variants and 2 in-frame indels."
Quantifies the NOTCH1 contribution with a confidence interval and characterises the variant classes involved.
💊

Medical Actions

7
Complete surgical repair
Action: Surgical ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. NCIT:C15329
The definitive treatment, consisting of patch closure of the ventricular septal defect and relief of outflow obstruction by infundibular resection, with a transannular patch where the pulmonary annulus is too small to preserve. The trade-off embedded in that last decision is the central surgical judgement of this disease. A transannular patch relieves the obstruction most completely and guarantees pulmonary regurgitation for life, so valve-sparing techniques are preferred wherever annulus size permits.
Mechanism Target:
BYPASSES Malalignment ventricular septal defect with overriding aorta — Patch closure eliminates the communication and restores the aorta to the left ventricle.
BYPASSES Right ventricular outflow tract obstruction — Infundibular resection and, where needed, a transannular patch relieve the obstruction.
Show evidence (1 reference)
PMID:39569497 SUPPORT Human Clinical
"Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot"
PARTIAL, and cited here as the cost of the operation rather than its benefit. Nearly universal residual outflow dysfunction is what the repair trades for survival, and recording it on the treatment itself keeps that trade visible.
Beta-blockade for hypercyanotic spells
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: propranolol CHEBI:8499 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses propranolol (CHEBI:8499). CHEBI:8499 is a therapeutic agent from Chemical Entities of Biological Interest.
Propranolol reduces dynamic infundibular constriction, used acutely during a spell and as prophylaxis in infants awaiting repair. It is the one pharmacotherapy in this disease that acts on the actual mechanism of the acute event rather than on its consequences.
Mechanism Target:
INHIBITS Right ventricular outflow tract obstruction — Beta-blockade relaxes the dynamic muscular component of the obstruction, which is the part that acutely worsens during a spell.
Systemic vasoconstriction for hypercyanotic spells
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: phenylephrine CHEBI:8093 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses phenylephrine (CHEBI:8093). CHEBI:8093 is a therapeutic agent from Chemical Entities of Biological Interest.
Phenylephrine raises systemic vascular resistance and so reverses the resistance gradient that is driving right to left shunting. It is the pharmacological version of what a squatting child does mechanically, and it is a direct clinical application of the shunt-direction node in this entry.
Mechanism Target:
MODULATES Shunt direction determined by outflow resistance — Raising systemic resistance shifts the balance back towards pulmonary flow.
Prostaglandin E1 for ductal-dependent pulmonary blood flow
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: alprostadil CHEBI:15544 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses alprostadil, annotated with prostaglandin E1 (CHEBI:15544). CHEBI:15544 is a therapeutic agent from Chemical Entities of Biological Interest.
Alprostadil maintains ductal patency in neonates whose pulmonary blood flow depends on the duct, buying time to intervention. It treats neither the septal defect nor the obstruction, and is purely a holding measure.
Mechanism Target:
MODULATES Cyanosis and chronic hypoxaemia — Maintaining the duct provides an alternative source of pulmonary blood flow.
Systemic to pulmonary shunt palliation
Action: Surgical ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. NCIT:C15329
A modified Blalock-Taussig-Thomas shunt, or increasingly a transcatheter alternative such as outflow tract or ductal stenting, provides pulmonary blood flow in neonates too small or too high-risk for primary repair, and allows the pulmonary arteries to grow so that a transannular incision may later be avoided.
Mechanism Target:
MODULATES Cyanosis and chronic hypoxaemia — An alternative source of pulmonary blood flow raises systemic saturation without correcting the underlying anatomy.
Pulmonary valve replacement after repair
Action: Surgical ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Surgical Procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. NCIT:C15329
The principal late reintervention, for symptomatic or haemodynamically significant chronic pulmonary regurgitation. It improves symptoms and is associated with a fall in ventricular tachycardia incidence, but current guidance does not accept arrhythmia risk alone as an indication, because the evidence that valve replacement reduces subsequent arrhythmia risk is not robust. That reservation is curated deliberately, since the intuitive inference from the remodelling mechanism is that restoring valve competence should reverse the substrate, and that inference is not established.
Mechanism Target:
BYPASSES Postoperative pulmonary regurgitation and right ventricular remodelling — Replacing the incompetent valve removes the regurgitant volume load driving right ventricular dilation.
Show evidence (1 reference)
PMID:39569497 SUPPORT Human Clinical
"In addition, this scientific statement explores contemporary evidence for clinical choices such as transcatheter or surgical pulmonary valve replacement, discusses criteria and options for intervention for failing implanted bioprosthetic pulmonary valves, and considers a new approach to..."
States that optimal timing and indications for this intervention are being reconsidered rather than settled, which is precisely the open question this entry curates as a discussion.
Implantable cardioverter defibrillator and catheter ablation
Action: Therapeutic ProcedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic Procedure (NCIT:C49236). NCIT:C49236 is a clinical intervention from the NCI Thesaurus. NCIT:C49236
Device therapy and ablation for the late ventricular arrhythmia of repaired disease. They are curated here so the arrhythmia node is not a dead end in the pathograph, and because they act on the arrhythmia itself rather than on the substrate that produces it. That distinction is the point of the timing discussion in this entry: valve replacement is the only intervention that could plausibly address the substrate, and it has not been shown to reduce arrhythmia risk.
Mechanism Target:
MODULATES Ventricular arrhythmia and sudden death risk — A defibrillator terminates the arrhythmia once it occurs and ablation modifies the reentrant circuit, neither of which reverses the underlying fibrosis and dilation.
Show evidence (1 reference)
PMID:39569497 SUPPORT Human Clinical
"including transcatheter and surgical pulmonary valve replacement strategies, as well as management of life-threatening arrhythmias"
Names management of life-threatening arrhythmias as a distinct therapeutic domain in repaired disease, alongside valve replacement, which is the separation this treatment and the valve replacement treatment are curated to preserve.
🌍

Environmental Factors

1
Maternal pregestational diabetes
No ECTO term is bound. Maternal pregestational diabetes is a maternal disease state rather than an exposure to an agent, and the exposure hierarchy has no term expressing it without asserting a specific chemical exposure the sources do not support.
The best-characterised teratogenic exposure for this malformation and the only readily modifiable one. First-trimester hyperglycaemia acts during the same three to eight week window in which the outflow tract septates, which is why the exposure has to precede recognition of the pregnancy to matter. A meta-analysis of population-based studies covering over 80 million births gives a disease-specific relative risk of 1.41 for gestational diabetes, and reports that the risks for pre-gestational diabetes are higher still. The pre-gestational disease-specific estimate is not quoted here because it appears in the paper only as a forest plot figure rather than in quotable text, so what is asserted is the direction and the gestational figure rather than a pre-gestational number this entry cannot cite.
Show evidence (3 references)
PMID:35104296 SUPPORT Human Clinical
"offspring of women with GDM had an increased risk of heterotaxia (RR = 5.70, 95% CI 1.09 to 29.92, I2 = 85.7%, P = 0.008), tetralogy of Fallot (RR = 1.41, 95% CI 1.20 to 1.66, I2 = 0%, P = 0.600)"
A disease-specific relative risk for this malformation with a confidence interval clear of one, and with zero heterogeneity across the contributing studies, from a meta-analysis of over 80 million births.
PMID:35104296 SUPPORT Human Clinical
"The RRs of overall CAs and CHDs in offspring of women with PGDM were higher than those in offspring of women with GDM."
Establishes that pre-gestational diabetes carries the higher risk of the two, which is the direction this exposure entry asserts. The disease-specific pre-gestational figure appears in the paper only as a forest plot, so it is not quoted.
PMID:31454511 SUPPORT Human Clinical
"That analysis reported strong associations for pregestational diabetes with several birth defects, but few exposures among some of the less common birth defects led to unstable estimates with wide confidence intervals."
PARTIAL. Corroborates the pre-gestational association at the level of birth defects generally, and notes the imprecision that affects rarer defects.
Mechanism Target:
PREDISPOSES Second heart field and cardiac neural crest program disruption — Maternal hyperglycaemia during outflow tract septation is proposed to perturb the progenitor and neural crest program, though the teratogenic mechanism is not established.
Show evidence (1 reference)
PMID:31454511 SUPPORT Human Clinical
"however, the teratogenic mechanism behind the increase risk for birth defects is still unknown"
PARTIAL, and quoted precisely because it states the limitation. Maternal diabetes is an established teratogen, and the step from that association to this particular developmental program is not evidenced.
🔬

Diagnosis

2
Transthoracic echocardiography
The diagnostic modality, defining the septal defect, the degree of aortic override, the level and severity of outflow obstruction, and the arch sidedness. Definition of coronary anatomy before operation is a specific requirement rather than an optional refinement, because an anomalous vessel crossing the outflow tract changes the operation.
Show evidence (1 reference)
PMID:32156463 SUPPORT Human Clinical
"Knowledge of coronary anatomy prior to corrective surgery is vital to avoid damage to vessels crossing the right ventricular outflow tract (RVOT)."
States that defining coronary anatomy before operation is required rather than optional, which is the specific diagnostic claim made here.
Genetic testing including 22q11.2 deletion analysis
Worth performing in every case even though most results are negative, because the eighteen percent with an identifiable aberration acquire extracardiac surveillance and altered recurrence counselling as a result.
Show evidence (1 reference)
PMID:19948535 SUPPORT Human Clinical
"230 patients with ToF were studied by karyotyping, comprehensive 22q11.2 deletion testing and sequencing of TBX1, NKX2.5 and JAG1, as well as molecular karyotyping in selected patients."
Describes the testing strategy that produced the eighteen percent yield, which is what justifies testing unselected patients.
📈

Progression

4
Fetal and neonatal period
The malformation is complete by the eighth week of gestation and is increasingly detected on antenatal screening. At birth the presentation is decided by the severity of outflow obstruction. Severe obstruction gives ductal-dependent pulmonary blood flow and cyanosis from the first hours; mild obstruction gives a well-looking infant with a murmur.
Infancy
Dynamic infundibular obstruction typically worsens over the first weeks to months, so a child who was pink at birth may become cyanotic and begin to have hypercyanotic spells, classically between two and four months. This is the period of greatest risk before repair, and the reason repair is not deferred indefinitely.
Surgical repair
Complete repair is now usually performed in the first year, often electively in the first months. Operative survival is high in well-resourced settings, which is what has converted this from a disease of childhood mortality into a lifelong condition of adults.
Adult survivorship after repair
Decades of pulmonary regurgitation, progressive right ventricular dilation, exercise intolerance, atrial and ventricular arrhythmia, and the question of when to replace the pulmonary valve. The population in this phase is growing and is the one in which most contemporary uncertainty about this disease now lies.
📊

Prevalence

1
Worldwide
Birth Prevalence 1–9 per 10,000
The most common cyanotic congenital heart disease, accounting for roughly a tenth of all congenital heart disease. The class here is coarse because no cited source in this entry states a rate.
Show evidence (1 reference)
PMID:34905512 SUPPORT Human Clinical
"Tetralogy of Fallot (TOF) is the most common cyanotic heart defect, yet the underlying genetic mechanisms remain poorly understood."
PARTIAL. Establishes the rank among cyanotic defects but states no rate, so the prevalence class is coarse and no numeric figure is asserted.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Tetralogy of Fallot:

Persistent truncus arteriosus
Overlapping Features The other conotruncal malformation of the same developmental program, and the closest mechanistic relative. In truncus the outflow tract fails to septate at all, leaving one vessel; here it septates in the wrong position. The physiological consequence is opposite in a way that matters clinically, since truncus produces unobstructed pulmonary overcirculation and heart failure, whereas this disease produces obstructed pulmonary flow and cyanosis.
Double outlet right ventricle
Overlapping Features Overlaps anatomically and the distinction can be arbitrary, resting on the degree of aortic override, conventionally at a fifty percent threshold.
Pulmonary atresia with ventricular septal defect
Overlapping Features Best regarded as the severe end of this disease's own spectrum rather than a separate entity, with pulmonary blood flow dependent on the duct or on collateral arteries.
🧫

Experimental Models

1
Hey2 mutant mouse OTHER
A mouse null for the Notch effector Hey2 develops tetralogy of Fallot along with other congenital heart defects, which is one of the few models that reproduces the specific malformation rather than a general outflow tract abnormality. It is mechanistically informative because it places a Notch pathway effector upstream of this precise anatomy, at a time when the human evidence for Notch involvement was limited to JAG1 in Alagille syndrome.
Organism
house mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in house mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Publication
PMID:12372254
Pathograph links
Second heart field and cardiac neural crest program disruption Loss of a Notch pathway effector perturbs the developmental program of the outflow tract.
Anterocephalad deviation of the outlet septum The mutant reproduces the malformation itself rather than an unrelated cardiac defect.
Show evidence (2 references)
PMID:12372254 SUPPORT Model Organism
"Recent studies have implicated the Notch signaling pathway in human cardiac development by demonstrating abnormalities of the JAG1 gene as the basis for Alagille syndrome and some cases of isolated tetralogy of Fallot or pulmonic stenosis."
States the human Notch evidence that motivated the model, and connects it to the JAG1 gene curated in this entry.
PMID:12372254 SUPPORT Model Organism
"the Hey family of basic helix-loop-helix (bHLH) transcription factors are candidates for mediating Notch signaling in the developing cardiovascular system"
Establishes the rationale for targeting this specific effector, which is what makes the resulting phenotype mechanistically interpretable rather than incidental.
{ }

Source YAML

click to show 
name: Tetralogy of Fallot
creation_date: "2026-08-10T00:20:00Z"
category: Complex
disease_term:
  preferred_term: tetralogy of fallot
  term:
    id: MONDO:0008542
    label: tetralogy of fallot
description: >
  The most common cyanotic congenital heart disease. The name is a historical accident that
  obscures the mechanism: the four cardinal features are not four defects but four consequences
  of one, namely anterocephalad deviation of the outlet septum during outflow tract septation.
  A septum that deviates cannot close the interventricular communication, cannot leave the aorta
  aligned over the left ventricle, and cannot leave the subpulmonary infundibulum a normal
  calibre, and the right ventricle then hypertrophies against the resulting load. Everything
  clinically important follows from the severity of that last obstruction, which determines
  whether blood shunts left to right or right to left, and therefore whether the child is pink
  or blue.
parents:
- conotruncal heart defect
- cyanotic congenital heart disease

classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
    notes: >-
      A structural congenital cardiovascular malformation. The syndromic subgroup, principally
      22q11.2 deletion, carries immune, endocrine, and neurodevelopmental features outside this
      chapter; the entity curated here is the cardiac lesion.

pathophysiology:
- name: Second heart field and cardiac neural crest program disruption
  biological_scale: CELLULAR
  description: >
    A genetic lesion or teratogenic insult perturbs addition of second heart field progenitors to
    the developing outflow tract and migration of cardiac neural crest cells into it, during weeks
    three to eight of gestation. This is the same developmental program whose failure produces
    persistent truncus arteriosus, and the two diseases are best read as different severities and
    positions of failure in one process rather than as unrelated malformations.
  cell_types:
  - preferred_term: migratory cardiac neural crest cell
    term:
      id: CL:2000073
      label: migratory cardiac neural crest cell
  - preferred_term: outflow tract myogenic progenitor
    term:
      id: CL:0000513
      label: cardiac muscle myoblast
  biological_processes:
  - preferred_term: outflow tract morphogenesis
    term:
      id: GO:0003151
      label: outflow tract morphogenesis
    modifier: DECREASED
  - preferred_term: cardiac neural crest cell development
    term:
      id: GO:0061308
      label: cardiac neural crest cell development involved in heart development
    modifier: DECREASED
  locations:
  - preferred_term: outflow tract septum
    term:
      id: UBERON:0004142
      label: outflow tract septum
  downstream:
  - target: Anterocephalad deviation of the outlet septum
    causal_link_type: DIRECT
    description: >
      A disrupted progenitor and neural crest program produces a septum that forms in the wrong
      position rather than failing to form at all.
  evidence:
  - reference: PMID:34905512
    reference_title: "Sequencing of a Chinese tetralogy of Fallot cohort reveals clustering mutations in myogenic heart progenitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We discovered that the candidate gene expression was enriched in the myogenic progenitors of the cardiac outflow tract."
    explanation: Localises the genes carrying damaging de novo variants in this disease to the specific progenitor population of the outflow tract, which is the cellular claim this node makes.
  - reference: PMID:34905512
    reference_title: "Sequencing of a Chinese tetralogy of Fallot cohort reveals clustering mutations in myogenic heart progenitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To assess the impact of these mutations on early cardiac development, we integrated single-cell and spatial transcriptomics of early human heart development with our genetic findings."
    explanation: States the method that joins the genetic findings to a developmental cell population, which is what makes the localisation more than an association.

- name: Anterocephalad deviation of the outlet septum
  biological_scale: TISSUE
  description: >
    The single anatomical lesion of this disease. The muscular outlet septum deviates
    anterocephalad relative to the muscular ventricular septum. Every one of the four cardinal
    features is a geometric consequence of that one deviation, which is why they occur together
    with essentially no exceptions and why the eponymous tetralogy is better understood as a
    monad.
  biological_processes:
  - preferred_term: outflow tract septum morphogenesis
    term:
      id: GO:0003148
      label: outflow tract septum morphogenesis
    modifier: DECREASED
  locations:
  - preferred_term: interventricular septum
    term:
      id: UBERON:0002094
      label: interventricular septum
  downstream:
  - target: Malalignment ventricular septal defect with overriding aorta
    causal_link_type: DIRECT
    description: >
      A deviated septum cannot close the interventricular communication, and leaves the aortic
      root straddling it.
  - target: Right ventricular outflow tract obstruction
    causal_link_type: DIRECT
    description: >
      The same deviation narrows the subpulmonary infundibulum.

- name: Malalignment ventricular septal defect with overriding aorta
  biological_scale: TISSUE
  description: >
    A large non-restrictive perimembranous defect, with the aortic valve annulus straddling it.
    Because the defect is non-restrictive, the two ventricles function as a single pumping
    chamber at systemic pressure, which is why the direction of shunting is decided entirely by
    the relative resistance of the two outflows rather than by the defect itself.
  locations:
  - preferred_term: interventricular septum
    term:
      id: UBERON:0002094
      label: interventricular septum
  downstream:
  - target: Shunt direction determined by outflow resistance
    causal_link_type: DIRECT
    description: >
      A non-restrictive communication allows flow to follow the path of least resistance.

- name: Right ventricular outflow tract obstruction
  biological_scale: TISSUE
  description: >
    Obstruction at infundibular, valvar, supravalvar, or branch pulmonary artery level, singly or
    in combination. The infundibular component is muscular and therefore dynamic, which is the
    mechanistic basis of the hypercyanotic spell and the reason severity can change from minute
    to minute in a way that fixed obstructions cannot.
  locations:
  - preferred_term: pulmonary valve
    term:
      id: UBERON:0002146
      label: pulmonary valve
  downstream:
  - target: Shunt direction determined by outflow resistance
    causal_link_type: DIRECT
    description: >
      Obstruction to pulmonary outflow raises the resistance against which the right ventricle
      must eject, relative to the systemic circuit.
  - target: Right ventricular hypertrophy
    causal_link_type: DIRECT
    description: >
      Chronic pressure loading of the right ventricle drives compensatory hypertrophy.

- name: Shunt direction determined by outflow resistance
  biological_scale: ORGANISM
  description: >
    The pivot of the whole disease. With a non-restrictive ventricular septal defect, flow goes
    wherever resistance is lower. Mild outflow obstruction leaves pulmonary resistance below
    systemic and the shunt is left to right, producing the acyanotic or pink presentation. Severe
    obstruction reverses that and produces right to left shunting with cyanosis. This is also why
    raising systemic vascular resistance, which squatting does mechanically and phenylephrine
    does pharmacologically, terminates a hypercyanotic spell.
  downstream:
  - target: Cyanosis and chronic hypoxaemia
    causal_link_type: DIRECT
    description: >
      Right to left shunting delivers systemic venous blood to the aorta without pulmonary gas
      exchange.

- name: Right ventricular hypertrophy
  biological_scale: TISSUE
  description: >
    Secondary and largely postnatal, developing as the right ventricle ejects against systemic
    level pressure. It is the one cardinal feature that is a response rather than a malformation,
    which is why it is not present at the same severity from birth.
  biological_processes:
  - preferred_term: cardiac muscle hypertrophy
    term:
      id: GO:0003300
      label: cardiac muscle hypertrophy
    modifier: INCREASED
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell

- name: Cyanosis and chronic hypoxaemia
  biological_scale: ORGANISM
  description: >
    Chronic arterial desaturation, with compensatory polycythaemia and, over years, digital
    clubbing. In the modern era of early repair these late consequences are increasingly historical
    in high-income settings and remain common where surgery is delayed.
  downstream:
  - target: Postoperative pulmonary regurgitation and right ventricular remodelling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Cyanosis is what forces early operation, and the operation itself creates the late lesion.

- name: Postoperative pulmonary regurgitation and right ventricular remodelling
  biological_scale: ORGANISM
  description: >
    The defining problem of the adult with repaired tetralogy, and an iatrogenic one. Relieving
    the outflow obstruction, especially with a transannular patch, leaves the pulmonary valve
    incompetent. Decades of free pulmonary regurgitation then dilate the right ventricle, drive
    fibrosis, and build an arrhythmogenic substrate. The disease of the survivor is therefore not
    the disease that was repaired, which is the central fact of lifelong follow-up in this
    population.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: INCREASED
  downstream:
  - target: Ventricular arrhythmia and sudden death risk
    causal_link_type: DIRECT
    description: >
      Right ventricular dilation and fibrosis create the substrate for reentrant ventricular
      tachycardia.
  evidence:
  - reference: PMID:39569497
    reference_title: "Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot, precipitating a complex pathophysiological cascade that leads to increasing rates of morbidity and mortality with advancing age."
    explanation: States that outflow dysfunction after repair is nearly universal and drives a cascade of rising morbidity and mortality with age, which is exactly the claim this node makes about the repair creating the next disease.

- name: Ventricular arrhythmia and sudden death risk
  biological_scale: ORGANISM
  description: >
    The principal late cause of death after successful repair. It is deliberately not curated as
    conforming to cardiac_ion_channel_repolarization, because the substrate here is structural,
    consisting of surgical scar and fibrosis in a dilated ventricle, rather than a primary
    channelopathy in a structurally normal heart.
  evidence:
  - reference: PMID:27329296
    reference_title: "Approach to residual pulmonary valve dysfunction in adults with repaired tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chronic severe pulmonary regurgitation as a result of surgical repair can lead to myriad complications including right ventricular dysfunction, decreased exercise tolerance, right heart failure and symptomatic arrhythmias."
    explanation: Attributes the late complications directly to the surgical repair, and names symptomatic arrhythmias among them, which is the specific claim this node makes.

phenotypes:
- category: Clinical
  name: Ventricular septal defect
  description: >
    Obligate. A large malalignment perimembranous defect, present in every case by definition.
  phenotype_term:
    preferred_term: Ventricular septal defect
    term:
      id: HP:0001629
      label: Ventricular septal defect
  frequency: OBLIGATE

- category: Clinical
  name: Overriding aorta
  description: >
    Obligate. The aortic valve annulus straddles the septal defect.
  phenotype_term:
    preferred_term: Overriding aorta
    term:
      id: HP:0002623
      label: Overriding aorta
  frequency: OBLIGATE

- category: Clinical
  name: Right ventricular outflow tract obstruction
  description: >
    Obligate in presence though highly variable in severity, ranging from mild infundibular
    narrowing to complete pulmonary atresia. That variability is what generates the entire
    clinical spectrum of this disease.
  phenotype_term:
    preferred_term: Pulmonic stenosis
    term:
      id: HP:0001642
      label: Pulmonic stenosis
  frequency: OBLIGATE

- category: Clinical
  name: Right ventricular hypertrophy
  description: >
    Obligate but secondary, developing in response to pressure loading rather than being present
    as a malformation from the outset.
  phenotype_term:
    preferred_term: Right ventricular hypertrophy
    term:
      id: HP:0001667
      label: Right ventricular hypertrophy
  frequency: OBLIGATE

- category: Clinical
  name: Cyanosis
  description: >
    Variable, and its timing is diagnostic of severity. Present from birth with severe outflow
    obstruction, emerging over weeks to months as dynamic infundibular obstruction progresses, or
    absent altogether in the acyanotic pink presentation.
  phenotype_term:
    preferred_term: Cyanosis
    term:
      id: HP:0000961
      label: Cyanosis

- category: Clinical
  name: Hypercyanotic spells
  description: >
    Paroxysmal deep cyanosis with hyperpnoea and irritability, typically in infants of two to four
    months, caused by acute dynamic infundibular constriction abruptly increasing right to left
    shunting. No precise HPO term exists for the episodic entity, so this phenotype is bound to
    Cyanosis with a recurrent temporality qualifier rather than to an invented or approximate term.
    The spell is the reason this disease is an emergency rather than merely a malformation.
  phenotype_term:
    preferred_term: Hypercyanotic spell
    term:
      id: HP:0000961
      label: Cyanosis
    temporality: RECURRENT

- category: Clinical
  name: Heart murmur
  description: >
    A harsh systolic ejection murmur at the left upper sternal border, arising from the outflow
    obstruction rather than from the septal defect. Its intensity falls during a hypercyanotic
    spell, because less blood is crossing the obstruction, which is a counterintuitive and
    clinically vital sign.
  phenotype_term:
    preferred_term: Heart murmur
    term:
      id: HP:0030148
      label: Heart murmur

- category: Clinical
  name: Digital clubbing
  description: >
    A late consequence of chronic hypoxaemia, now largely historical where early repair is
    available.
  phenotype_term:
    preferred_term: Clubbing of fingers
    term:
      id: HP:0100759
      label: Clubbing of fingers

- category: Laboratory
  name: Polycythaemia
  description: >
    Compensatory erythrocytosis driven by chronic arterial desaturation.
  phenotype_term:
    preferred_term: Polycythemia
    term:
      id: HP:0001901
      label: Polycythemia

- category: Clinical
  name: Failure to thrive
  description: >
    Seen with significant cyanosis or heart failure.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive

- category: Clinical
  name: Right aortic arch
  description: >
    Present in roughly a quarter of cases overall and considerably more often in the 22q11.2
    deleted subgroup. It is a patterning anomaly of the same pharyngeal arch program, not a
    consequence of the septal deviation.
  phenotype_term:
    preferred_term: Right aortic arch with mirror image branching
    term:
      id: HP:0002627
      label: Right aortic arch with mirror image branching

- category: Clinical
  name: Anomalous coronary artery crossing the outflow tract
  description: >
    Uncommon but surgically decisive. A left anterior descending artery arising from the right
    coronary and crossing the right ventricular outflow tract can be transected by the very
    incision used to relieve the obstruction, which is why coronary anatomy is defined before
    operation rather than discovered during it.
  phenotype_term:
    preferred_term: Anomalous coronary artery arising from the opposite sinus
    term:
      id: HP:0025503
      label: Anomalous coronary artery arising from the opposite sinus
  evidence:
  - reference: PMID:32156463
    reference_title: "Coronary anomalies in tetralogy of Fallot - A meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An anomalous coronary artery is reported in 2% to 23% of patients with tetralogy of Fallot (TOF). Knowledge of coronary anatomy prior to corrective surgery is vital to avoid damage to vessels crossing the right ventricular outflow tract (RVOT)."
    explanation: Gives the reported prevalence range and states the surgical consequence, which is the reason this phenotype is curated at all. No frequency band is assigned because a range spanning 2 to 23 percent crosses the OCCASIONAL and FREQUENT boundaries and the meta-analysis is reporting heterogeneity rather than a point estimate.

genetic:
- name: 22q11.2 deletion
  gene_term:
    preferred_term: TBX1
    term:
      id: hgnc:11592
      label: TBX1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    The single most common identifiable genetic cause, found in roughly seven percent of an
    unselected cohort. TBX1 haploinsufficiency is the principal candidate within the deleted
    interval, acting on second heart field progenitor addition. Identifying it changes management
    beyond the heart, because it brings immune, endocrine, and neurodevelopmental surveillance
    with it.
  evidence:
  - reference: PMID:19948535
    reference_title: "Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic genetic aberrations were found in 42 patients (18%), with 22q11.2 deletion as the most common diagnosis (7.4%), followed by trisomy 21 (5.2%) and other chromosomal aberrations or submicroscopic copy number changes (3%)."
    explanation: Quantifies the deletion as the most common identifiable cause in an unselected cohort of 230 patients, with a counted denominator.

- name: JAG1
  gene_term:
    preferred_term: JAG1
    term:
      id: hgnc:6188
      label: JAG1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Notch ligand, mutated in Alagille syndrome and in some isolated cases. Its involvement is what
    first implicated Notch signalling in human outflow tract development.
  evidence:
  - reference: PMID:19948535
    reference_title: "Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in JAG1 were detected in three patients with Alagille syndrome (1.3%), while NKX2.5 mutations were seen in two patients with non-syndromic ToF (0.9%)."
    explanation: Quantifies the JAG1 and NKX2-5 contributions in the same cohort, with counted denominators.

- name: NKX2-5
  gene_term:
    preferred_term: NKX2-5
    term:
      id: hgnc:2488
      label: NKX2-5
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    Cardiac transcription factor, mutated in a small fraction of nonsyndromic cases.
  evidence:
  - reference: PMID:19948535
    reference_title: "Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations in JAG1 were detected in three patients with Alagille syndrome (1.3%), while NKX2.5 mutations were seen in two patients with non-syndromic ToF (0.9%)."
    explanation: Quantifies the NKX2-5 contribution at 0.9 percent of an unselected cohort, which is what places it among the minor rather than major contributors.

- name: FLT4
  gene_term:
    preferred_term: FLT4
    term:
      id: hgnc:3767
      label: FLT4
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    VEGFR3. Identified by whole exome sequencing as one of the two largest single-gene
    contributors to nonsyndromic disease, alongside NOTCH1. Its emergence was a genuine surprise,
    since the gene was known for lymphatic rather than cardiac development.
  evidence:
  - reference: PMID:30582441
    reference_title: "Whole Exome Sequencing Reveals the Major Genetic Contributors to Nonsyndromic Tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The NOTCH1 locus is the most frequent site of genetic variants predisposing to nonsyndromic TOF, followed by FLT4. Together, variants in these genes are found in almost 7% of TOF patients."
    explanation: Ranks FLT4 as the second most frequent contributor after NOTCH1 and quantifies their combined yield at almost seven percent of patients, from a cohort of 829 undergoing whole exome sequencing.

- name: NOTCH1
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >
    The single most frequent site of genetic variants predisposing to nonsyndromic disease,
    consistent with the established role of Notch signalling in outflow tract septation and neural
    crest patterning.
  evidence:
  - reference: PMID:30582441
    reference_title: "Whole Exome Sequencing Reveals the Major Genetic Contributors to Nonsyndromic Tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clustering of variants in 2 genes, NOTCH1 and FLT4, surpassed thresholds for genome-wide significance (assigned as P<5×10-8) after correction for multiple comparisons."
    explanation: Establishes that only these two genes reached genome-wide significance in a cohort of 829, which is what separates them from the many candidate genes proposed for this disease.
  - reference: PMID:30582441
    reference_title: "Whole Exome Sequencing Reveals the Major Genetic Contributors to Nonsyndromic Tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thirty-one changes were observed in 37 probands (4.5%; 95% CI, 3.2%-6.1%) and included 7 loss-of-function variants 22 missense variants and 2 in-frame indels."
    explanation: Quantifies the NOTCH1 contribution with a confidence interval and characterises the variant classes involved.

inheritance:
- name: Non-Mendelian with a Mendelian minority
  description: >
    Most cases are sporadic and multifactorial. A substantial minority, around eighteen percent in
    a comprehensively investigated cohort, carry an identifiable chromosomal or single-gene cause,
    the most common being the 22q11.2 deletion. The practical consequence is that genetic testing
    is worthwhile in every case despite most results being negative, because a positive result
    changes both extracardiac surveillance and recurrence counselling.
  inheritance_term:
    preferred_term: Non-Mendelian inheritance
    term:
      id: HP:0001426
      label: Non-Mendelian inheritance
  evidence:
  - reference: PMID:19948535
    reference_title: "Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic genetic aberrations were found in 42 patients (18%)"
    explanation: Quantifies the identifiable-cause fraction, which is what establishes that the majority is not Mendelian while a meaningful minority is.

environmental:
- name: Maternal pregestational diabetes
  description: >
    The best-characterised teratogenic exposure for this malformation and the only readily
    modifiable one. First-trimester hyperglycaemia acts during the same three to eight week window
    in which the outflow tract septates, which is why the exposure has to precede recognition of
    the pregnancy to matter. A meta-analysis of population-based studies covering over 80 million
    births gives a disease-specific relative risk of 1.41 for gestational diabetes, and reports
    that the risks for pre-gestational diabetes are higher still. The pre-gestational
    disease-specific estimate is not quoted here because it appears in the paper only as a forest
    plot figure rather than in quotable text, so what is asserted is the direction and the
    gestational figure rather than a pre-gestational number this entry cannot cite.
  influences_mechanisms:
  - target: Second heart field and cardiac neural crest program disruption
    environmental_effect: PREDISPOSES
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >
      Maternal hyperglycaemia during outflow tract septation is proposed to perturb the progenitor
      and neural crest program, though the teratogenic mechanism is not established.
    evidence:
    - reference: PMID:31454511
      reference_title: "Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "however, the teratogenic mechanism behind the increase risk for birth defects is still unknown"
      explanation: PARTIAL, and quoted precisely because it states the limitation. Maternal diabetes is an established teratogen, and the step from that association to this particular developmental program is not evidenced.
  evidence:
  - reference: PMID:35104296
    reference_title: "Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "offspring of women with GDM had an increased risk of heterotaxia (RR = 5.70, 95% CI 1.09 to 29.92, I2 = 85.7%, P = 0.008), tetralogy of Fallot (RR = 1.41, 95% CI 1.20 to 1.66, I2 = 0%, P = 0.600)"
    explanation: A disease-specific relative risk for this malformation with a confidence interval clear of one, and with zero heterogeneity across the contributing studies, from a meta-analysis of over 80 million births.
  - reference: PMID:35104296
    reference_title: "Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The RRs of overall CAs and CHDs in offspring of women with PGDM were higher than those in offspring of women with GDM."
    explanation: Establishes that pre-gestational diabetes carries the higher risk of the two, which is the direction this exposure entry asserts. The disease-specific pre-gestational figure appears in the paper only as a forest plot, so it is not quoted.
  - reference: PMID:31454511
    reference_title: "Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "That analysis reported strong associations for pregestational diabetes with several birth defects, but few exposures among some of the less common birth defects led to unstable estimates with wide confidence intervals."
    explanation: PARTIAL. Corroborates the pre-gestational association at the level of birth defects generally, and notes the imprecision that affects rarer defects.
  notes: >
    No ECTO term is bound. Maternal pregestational diabetes is a maternal disease state rather than
    an exposure to an agent, and the exposure hierarchy has no term expressing it without asserting
    a specific chemical exposure the sources do not support.

experimental_models:
- name: Hey2 mutant mouse
  description: >
    A mouse null for the Notch effector Hey2 develops tetralogy of Fallot along with other
    congenital heart defects, which is one of the few models that reproduces the specific
    malformation rather than a general outflow tract abnormality. It is mechanistically
    informative because it places a Notch pathway effector upstream of this precise anatomy, at a
    time when the human evidence for Notch involvement was limited to JAG1 in Alagille syndrome.
  experimental_model_type: OTHER
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  modeled_mechanisms:
  - target: Second heart field and cardiac neural crest program disruption
    description: >
      Loss of a Notch pathway effector perturbs the developmental program of the outflow tract.
  - target: Anterocephalad deviation of the outlet septum
    description: >
      The mutant reproduces the malformation itself rather than an unrelated cardiac defect.
  publication: PMID:12372254
  evidence:
  - reference: PMID:12372254
    reference_title: "Tetralogy of fallot and other congenital heart defects in Hey2 mutant mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Recent studies have implicated the Notch signaling pathway in human cardiac development by demonstrating abnormalities of the JAG1 gene as the basis for Alagille syndrome and some cases of isolated tetralogy of Fallot or pulmonic stenosis."
    explanation: States the human Notch evidence that motivated the model, and connects it to the JAG1 gene curated in this entry.
  - reference: PMID:12372254
    reference_title: "Tetralogy of fallot and other congenital heart defects in Hey2 mutant mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "the Hey family of basic helix-loop-helix (bHLH) transcription factors are candidates for mediating Notch signaling in the developing cardiovascular system"
    explanation: Establishes the rationale for targeting this specific effector, which is what makes the resulting phenotype mechanistically interpretable rather than incidental.

treatments:
- name: Complete surgical repair
  description: >
    The definitive treatment, consisting of patch closure of the ventricular septal defect and
    relief of outflow obstruction by infundibular resection, with a transannular patch where the
    pulmonary annulus is too small to preserve. The trade-off embedded in that last decision is
    the central surgical judgement of this disease. A transannular patch relieves the obstruction
    most completely and guarantees pulmonary regurgitation for life, so valve-sparing techniques
    are preferred wherever annulus size permits.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Malalignment ventricular septal defect with overriding aorta
    treatment_effect: BYPASSES
    description: >
      Patch closure eliminates the communication and restores the aorta to the left ventricle.
  - target: Right ventricular outflow tract obstruction
    treatment_effect: BYPASSES
    description: >
      Infundibular resection and, where needed, a transannular patch relieve the obstruction.
  evidence:
  - reference: PMID:39569497
    reference_title: "Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot"
    explanation: PARTIAL, and cited here as the cost of the operation rather than its benefit. Nearly universal residual outflow dysfunction is what the repair trades for survival, and recording it on the treatment itself keeps that trade visible.

- name: Beta-blockade for hypercyanotic spells
  description: >
    Propranolol reduces dynamic infundibular constriction, used acutely during a spell and as
    prophylaxis in infants awaiting repair. It is the one pharmacotherapy in this disease that
    acts on the actual mechanism of the acute event rather than on its consequences.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: propranolol
      term:
        id: CHEBI:8499
        label: propranolol
  target_mechanisms:
  - target: Right ventricular outflow tract obstruction
    treatment_effect: INHIBITS
    description: >
      Beta-blockade relaxes the dynamic muscular component of the obstruction, which is the part
      that acutely worsens during a spell.

- name: Systemic vasoconstriction for hypercyanotic spells
  description: >
    Phenylephrine raises systemic vascular resistance and so reverses the resistance gradient that
    is driving right to left shunting. It is the pharmacological version of what a squatting child
    does mechanically, and it is a direct clinical application of the shunt-direction node in this
    entry.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: phenylephrine
      term:
        id: CHEBI:8093
        label: phenylephrine
  target_mechanisms:
  - target: Shunt direction determined by outflow resistance
    treatment_effect: MODULATES
    description: >
      Raising systemic resistance shifts the balance back towards pulmonary flow.

- name: Prostaglandin E1 for ductal-dependent pulmonary blood flow
  description: >
    Alprostadil maintains ductal patency in neonates whose pulmonary blood flow depends on the
    duct, buying time to intervention. It treats neither the septal defect nor the obstruction, and
    is purely a holding measure.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: alprostadil
      term:
        id: CHEBI:15544
        label: prostaglandin E1
  target_mechanisms:
  - target: Cyanosis and chronic hypoxaemia
    treatment_effect: MODULATES
    description: >
      Maintaining the duct provides an alternative source of pulmonary blood flow.

- name: Systemic to pulmonary shunt palliation
  description: >
    A modified Blalock-Taussig-Thomas shunt, or increasingly a transcatheter alternative such as
    outflow tract or ductal stenting, provides pulmonary blood flow in neonates too small or too
    high-risk for primary repair, and allows the pulmonary arteries to grow so that a transannular
    incision may later be avoided.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Cyanosis and chronic hypoxaemia
    treatment_effect: MODULATES
    description: >
      An alternative source of pulmonary blood flow raises systemic saturation without correcting
      the underlying anatomy.

- name: Pulmonary valve replacement after repair
  description: >
    The principal late reintervention, for symptomatic or haemodynamically significant chronic
    pulmonary regurgitation. It improves symptoms and is associated with a fall in ventricular
    tachycardia incidence, but current guidance does not accept arrhythmia risk alone as an
    indication, because the evidence that valve replacement reduces subsequent arrhythmia risk is
    not robust. That reservation is curated deliberately, since the intuitive inference from the
    remodelling mechanism is that restoring valve competence should reverse the substrate, and
    that inference is not established.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Postoperative pulmonary regurgitation and right ventricular remodelling
    treatment_effect: BYPASSES
    description: >
      Replacing the incompetent valve removes the regurgitant volume load driving right
      ventricular dilation.
    evidence:
    - reference: PMID:39569497
      reference_title: "Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In addition, this scientific statement explores contemporary evidence for clinical choices such as transcatheter or surgical pulmonary valve replacement, discusses criteria and options for intervention for failing implanted bioprosthetic pulmonary valves, and considers a new approach to determining optimal timing and indications for pulmonary valve replacement."
      explanation: States that optimal timing and indications for this intervention are being reconsidered rather than settled, which is precisely the open question this entry curates as a discussion.

- name: Implantable cardioverter defibrillator and catheter ablation
  description: >
    Device therapy and ablation for the late ventricular arrhythmia of repaired disease. They are
    curated here so the arrhythmia node is not a dead end in the pathograph, and because they act
    on the arrhythmia itself rather than on the substrate that produces it. That distinction is the
    point of the timing discussion in this entry: valve replacement is the only intervention that
    could plausibly address the substrate, and it has not been shown to reduce arrhythmia risk.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: Therapeutic Procedure
    term:
      id: NCIT:C49236
      label: Therapeutic Procedure
  target_mechanisms:
  - target: Ventricular arrhythmia and sudden death risk
    treatment_effect: MODULATES
    description: >
      A defibrillator terminates the arrhythmia once it occurs and ablation modifies the reentrant
      circuit, neither of which reverses the underlying fibrosis and dilation.
    evidence:
    - reference: PMID:39569497
      reference_title: "Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "including transcatheter and surgical pulmonary valve replacement strategies, as well as management of life-threatening arrhythmias"
      explanation: Names management of life-threatening arrhythmias as a distinct therapeutic domain in repaired disease, alongside valve replacement, which is the separation this treatment and the valve replacement treatment are curated to preserve.

diagnosis:
- name: Transthoracic echocardiography
  description: >
    The diagnostic modality, defining the septal defect, the degree of aortic override, the level
    and severity of outflow obstruction, and the arch sidedness. Definition of coronary anatomy
    before operation is a specific requirement rather than an optional refinement, because an
    anomalous vessel crossing the outflow tract changes the operation.
  evidence:
  - reference: PMID:32156463
    reference_title: "Coronary anomalies in tetralogy of Fallot - A meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Knowledge of coronary anatomy prior to corrective surgery is vital to avoid damage to vessels crossing the right ventricular outflow tract (RVOT)."
    explanation: States that defining coronary anatomy before operation is required rather than optional, which is the specific diagnostic claim made here.

- name: Genetic testing including 22q11.2 deletion analysis
  description: >
    Worth performing in every case even though most results are negative, because the eighteen
    percent with an identifiable aberration acquire extracardiac surveillance and altered
    recurrence counselling as a result.
  evidence:
  - reference: PMID:19948535
    reference_title: "Comprehensive genotype-phenotype analysis in 230 patients with tetralogy of Fallot."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "230 patients with ToF were studied by karyotyping, comprehensive 22q11.2 deletion testing and sequencing of TBX1, NKX2.5 and JAG1, as well as molecular karyotyping in selected patients."
    explanation: Describes the testing strategy that produced the eighteen percent yield, which is what justifies testing unselected patients.

progression:
- phase: Fetal and neonatal period
  notes: >
    The malformation is complete by the eighth week of gestation and is increasingly detected on
    antenatal screening. At birth the presentation is decided by the severity of outflow
    obstruction. Severe obstruction gives ductal-dependent pulmonary blood flow and cyanosis from
    the first hours; mild obstruction gives a well-looking infant with a murmur.
- phase: Infancy
  notes: >
    Dynamic infundibular obstruction typically worsens over the first weeks to months, so a child
    who was pink at birth may become cyanotic and begin to have hypercyanotic spells, classically
    between two and four months. This is the period of greatest risk before repair, and the reason
    repair is not deferred indefinitely.
- phase: Surgical repair
  notes: >
    Complete repair is now usually performed in the first year, often electively in the first
    months. Operative survival is high in well-resourced settings, which is what has converted this
    from a disease of childhood mortality into a lifelong condition of adults.
- phase: Adult survivorship after repair
  notes: >
    Decades of pulmonary regurgitation, progressive right ventricular dilation, exercise
    intolerance, atrial and ventricular arrhythmia, and the question of when to replace the
    pulmonary valve. The population in this phase is growing and is the one in which most
    contemporary uncertainty about this disease now lies.

prevalence:
- population: Worldwide
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  notes: >
    The most common cyanotic congenital heart disease, accounting for roughly a tenth of all
    congenital heart disease. The class here is coarse because no cited source in this entry
    states a rate.
  evidence:
  - reference: PMID:34905512
    reference_title: "Sequencing of a Chinese tetralogy of Fallot cohort reveals clustering mutations in myogenic heart progenitors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tetralogy of Fallot (TOF) is the most common cyanotic heart defect, yet the underlying genetic mechanisms remain poorly understood."
    explanation: PARTIAL. Establishes the rank among cyanotic defects but states no rate, so the prevalence class is coarse and no numeric figure is asserted.

differential_diagnoses:
- name: Persistent truncus arteriosus
  description: >
    The other conotruncal malformation of the same developmental program, and the closest
    mechanistic relative. In truncus the outflow tract fails to septate at all, leaving one
    vessel; here it septates in the wrong position. The physiological consequence is opposite in
    a way that matters clinically, since truncus produces unobstructed pulmonary overcirculation
    and heart failure, whereas this disease produces obstructed pulmonary flow and cyanosis.
- name: Double outlet right ventricle
  description: >
    Overlaps anatomically and the distinction can be arbitrary, resting on the degree of aortic
    override, conventionally at a fifty percent threshold.
- name: Pulmonary atresia with ventricular septal defect
  description: >
    Best regarded as the severe end of this disease's own spectrum rather than a separate entity,
    with pulmonary blood flow dependent on the duct or on collateral arteries.

discussions:
- discussion_id: tetralogy_is_one_lesion_not_four
  kind: OPEN_QUESTION
  status: OPEN
  prompt: >
    Should the four cardinal features be modelled as one lesion with four consequences, and does
    the eponym actively mislead?
  rationale: >
    The historical name enumerates four findings as though they were four defects, and generations
    of teaching have followed that enumeration. The embryological account is that a single
    anterocephalad deviation of the outlet septum produces all four as geometric consequences, and
    this entry models it that way, with one node for the deviation and separate downstream nodes
    for the septal defect, the obstruction, and the hypertrophy. The modelling choice is not
    merely tidy. It predicts that the features cannot be dissociated, which is what is observed,
    and it correctly identifies right ventricular hypertrophy as secondary and postnatal rather
    than congenital. It also makes the severity spectrum intelligible, since one deviation of
    varying degree explains a continuum from pink tetralogy to pulmonary atresia, whereas four
    independent defects would not. What remains genuinely open is whether the molecular lesions
    converge on septal position specifically or on outflow tract development broadly, with septal
    deviation being only one of several possible outcomes.
  attaches_to:
  - pathophysiology#Anterocephalad deviation of the outlet septum
  - pathophysiology#Second heart field and cardiac neural crest program disruption
  evidence:
  - reference: PMID:34905512
    reference_title: "Sequencing of a Chinese tetralogy of Fallot cohort reveals clustering mutations in myogenic heart progenitors."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "We discovered that the candidate gene expression was enriched in the myogenic progenitors of the cardiac outflow tract."
    explanation: INDIRECT. Supports convergence of the genetic lesions on outflow tract development, which is the broader of the two readings; it does not establish that they converge on septal position specifically.
  proposed_experiments:
  - experiment_id: exp_tof_septal_position_quantification
    name: Quantitative morphometry of outlet septal position across genotype groups in fetal specimens
    description: >-
      Measure outlet septal deviation quantitatively across fetal specimens grouped by genotype,
      including 22q11.2 deleted, FLT4 or NOTCH1 variant, and genetically unexplained cases. If all
      genotypes converge on the same septal geometry, the single-lesion model holds across causes.
      If they differ systematically, the shared anatomy is a convergence point rather than the
      direct consequence of each lesion.

- discussion_id: the_repair_creates_the_next_disease
  kind: OPEN_QUESTION
  status: OPEN
  prompt: >
    Given that transannular repair reliably produces lifelong pulmonary regurgitation, and that
    valve replacement has not been shown to reduce arrhythmia risk, when should the valve be
    replaced?
  rationale: >
    This is the sharpest unresolved question in the modern management of this disease, and it
    exists because the operation succeeded. Relieving the outflow obstruction saved a generation of
    children and left them with an incompetent pulmonary valve, decades of right ventricular volume
    loading, and a late arrhythmic substrate. Valve replacement improves symptoms and is associated
    with lower observed ventricular tachycardia incidence, but current guidance declines to treat
    arrhythmia risk alone as an indication, because the evidence that replacement reduces
    subsequent arrhythmia is not robust. The clinician is therefore caught between operating early,
    committing a young patient to repeated prosthetic valve interventions over a lifetime, and
    operating late, by which point right ventricular remodelling may be irreversible. Resolving it
    requires knowing whether the fibrotic substrate regresses after unloading, which is a question
    about the biology of the remodelling node in this entry and not merely about trial design.
  attaches_to:
  - pathophysiology#Postoperative pulmonary regurgitation and right ventricular remodelling
  - pathophysiology#Ventricular arrhythmia and sudden death risk
  - treatments#Pulmonary valve replacement after repair
  proposed_experiments:
  - experiment_id: exp_pvr_timing_substrate_regression
    name: Serial cardiac magnetic resonance fibrosis mapping before and after pulmonary valve replacement stratified by preoperative right ventricular volume
    description: >-
      Follow patients undergoing pulmonary valve replacement with serial cardiac magnetic resonance
      fibrosis mapping and electrophysiological substrate assessment, stratified by preoperative
      right ventricular volume. The decision criterion is whether fibrotic burden regresses after
      unloading and whether that regression depends on operating before a volume threshold. A
      threshold effect would convert an open timing question into a measurable indication.

notes: >
  Deep-research provenance. Curated from a claude_code deep-research report treated as leads only.
  The report was detailed and explicitly asked that its ontology identifiers be verified before
  use, which was warranted.

  Deep-research provider ontology errors corrected. Three of the report's suggested identifiers
  were real CURIEs pointing at unrelated concepts, and three more had labels that did not match
  the identifier.

  CL:0002079 was suggested for cardiac neural crest cell and is actually pancreatic ductal cell.
  HP:0031264 was suggested for heart murmur and is actually Abnormal Bowman capsule morphology, a
  kidney term. HP:0004943 was suggested for the boot-shaped heart radiographic sign and is actually
  Accelerated atherosclerosis. HP:0001714 was suggested for right ventricular hypertrophy and is
  the generic Ventricular hypertrophy, so the specific HP:0001667 is used instead. HP:0004415 is
  real but is Pulmonary artery stenosis rather than the infundibular pulmonic stenosis the report
  labelled it. GO:0061308 is real but its canonical label is cardiac neural crest cell development
  involved in heart development, not involved in outflow tract morphogenesis as suggested.

  Absent bindings. HPO has no term for the
  boot-shaped heart radiographic sign, so that finding is not curated as a phenotype. HPO has no
  term for the hypercyanotic spell as an episodic entity, so it is bound to Cyanosis with a
  recurrent temporality qualifier rather than to an approximate term.

  Corrected term claims. An earlier revision of this entry asserted that CL has no cardiac neural
  crest cell term. That was wrong: CL:2000073 migratory cardiac neural crest cell exists and is
  used here, as it is in the sibling double outlet right ventricle and transposition entries. The
  outflow tract myogenic progenitor is likewise now bound to CL:0000513 cardiac muscle myoblast
  rather than to the generic cardiac muscle cell.

  Corrected provenance claims. An earlier revision of this entry asserted in three places that
  cached abstracts were truncated, and in one place that PMID:30582441 had no abstract body. All
  four claims were false. The caches are complete, and the apparent truncation was an artefact of
  a fixed-width extraction window used during curation rather than anything in the cache. Every
  affected snippet has been re-quoted at sentence boundaries from the full cached text.

  Module conformance. The late ventricular arrhythmia is deliberately not conformed to
  cardiac_ion_channel_repolarization, because its substrate is surgical scar and fibrosis in a
  dilated ventricle rather than a primary channelopathy in a structurally normal heart. This is the
  same judgement made for the atrial fibrillation of rheumatic heart disease.

  NEC preflight returned SKIP, since MONDO records no causal gene for this multifactorial disease.
  The manual fallback was run and passed. The OMIM identifier in the report, 187500, matches the
  OMIM cross-reference on MONDO:0008542 exactly, and the genes the report discusses most
  frequently, SHF, FLT4, NOTCH1, NKX2-5, and TBX1, are all genuine loci for this disease.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Tetralogy of Fallot (TOF): Comprehensive Disease Characteristics Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 71 citations 2026-08-10T00:54:56.844922

Tetralogy of Fallot (TOF): Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Tetralogy of Fallot (TOF) is the most common cyanotic congenital heart defect (CHD) and a member of the conotruncal (outflow-tract) family of malformations. It is defined by four anatomically related lesions arising from a single embryologic error — anterocephalad (superior and leftward) deviation/malalignment of the infundibular (outlet) septum relative to the muscular ventricular septum: (1) a large, non-restrictive ventricular septal defect (VSD, typically perimembranous, malalignment-type), (2) obstruction of the right ventricular outflow tract (RVOT)/pulmonary stenosis, (3) an aorta that overrides the VSD, and (4) secondary right ventricular hypertrophy (RVH) (StatPearls; Medscape).

Key identifiers: - OMIM: #187500 (Tetralogy of Fallot) (OMIM:187500) - Orphanet: ORPHA:3303 (with a related entry ORPHA:99068 for complete AV septal defect–TOF) (Orphanet) - MONDO: MONDO:0008542 - ICD-10-CM: Q21.3 (ICD10Data); ICD-9-CM: 745.2 - SNOMED CT: 86299006 - MeSH: D013771

Synonyms: Fallot tetralogy; TOF; TET; tetralogy of Fallot with pulmonic stenosis. Historically described by Niels Stensen (1672) and later systematically characterized by Étienne-Louis Arthur Fallot (1888).

Anatomic variants (per the International Society for Nomenclature of Paediatric and Congenital Heart Disease): TOF with pulmonary stenosis (classic form), TOF with pulmonary atresia (± major aortopulmonary collateral arteries, MAPCAs), TOF with absent pulmonary valve syndrome (APVS), and TOF with complete atrioventricular canal/septal defect (Medscape; ISUOG).

Evidence basis: Information below is aggregated across large clinical cohorts, national/regional birth-defect registries, surgical case series, and increasingly whole-exome/whole-genome sequencing cohorts (human clinical, aggregated at the disease level) supplemented by animal-model (mouse, zebrafish) mechanistic studies.

2. Etiology

Disease Causal Factors

TOF is a multifactorial disease arising from disruption of second heart field (SHF)–derived outflow tract myocardium and cardiac neural crest cell (CNCC) migration during weeks 3–8 of embryogenesis. Roughly 20–25% of cases occur as part of a recognized genetic syndrome or chromosomal abnormality; the remaining ~75–80% are "non-syndromic," with a minority of these attributable to identifiable monogenic causes and the majority presumed multifactorial/polygenic with contributing environmental exposures (StatPearls; PMC9582763).

Genetic Risk Factors

Chromosomal/syndromic causes (~20–25% of cases): - 22q11.2 deletion syndrome (DiGeorge/velocardiofacial syndrome) — the single most common identifiable genetic cause, found in ~15% of all TOF cases (7.4–15% across cohorts) (PMID:19948535; Circ Cardiovasc Genet). TBX1 is the principal dosage-sensitive gene within the deleted region. 22q11.2DS-associated TOF shows a distinctive phenotype: proximal pulmonary artery obstruction, hypoplastic central pulmonary arteries, right aortic arch (24%), and interrupted aortic arch (22–48%) (PMID:19948535). - Trisomy 21 (Down syndrome) — accounts for ~7% of TOF cases; ~5–10% of individuals with Down syndrome have TOF, and CHD overall occurs in ~40% of Down syndrome patients. - Trisomy 13, Trisomy 18 — less common associations. - Alagille syndrome (JAG1, less commonly NOTCH2) — Notch-pathway hepato-cardio-vertebral disorder; 1–2% of TOF patients carry pathogenic JAG1 variants (PMID:19948535; PMID:23956173). - CHARGE syndrome (CHD7) — TOF is relatively frequent among CHARGE-associated conotruncal defects. - VACTERL association — TOF among the cardiac component of this non-random constellation.

Monogenic/non-syndromic causal and susceptibility genes (whole-exome/genome sequencing cohorts): - NOTCH1 and FLT4 (VEGFR3) are the two most frequently implicated genes in large non-syndromic cohorts. In the largest published cohort (n=829), deleterious variants in NOTCH1 were found in ~4.5% and FLT4 in ~2.4% of patients, "together explaining ~7% of non-syndromic TOF cases" (PMID:30582441; PMC12940485). NOTCH1 variants are predominantly missense; FLT4 variants are predominantly loss-of-function. Expanding to nine candidate genes captures ~15–16% of non-syndromic cases. - NKX2-5 (OMIM 600584) — present in ≥4% of TOF patients (PMID:19948535); mutations identified in TOF patients often map outside the homeodomain and are incompletely penetrant, unlike classical homeodomain-disrupting NKX2-5 mutations causing isolated ASD/AV block (Circulation, hc4601.098427). - GATA4, GATA6, TBX5, TBX1, ZFPM2 (FOG2), FOXC2. - Signaling-pathway genes: JAG1, KDR, NFATC1, PTPN11, PDGFRA, SMAD2/SMAD4. - Emerging/splicing-associated candidates: PUF60, DVL3, FLNA (X-linked), MEIS2, SOX11, FLRT2, FKBP10, MST1R, GNE. - Ciliary genes: DNAH11, DYNC2H1, C2CD3, OFD1 (PMC12940485). - NEDD4 — a 2025 mouse-and-human study identified a human NEDD4* variant associated with TOF; NEDD4 controls DKK1 levels in neural crest cells to modulate Wnt signaling in the SHF (bioRxiv/PMC12913648, model-organism + human variant evidence).

Common/susceptibility variants (GWAS): - Loci at 12q24 and 13q32 reached genome-wide significance in a European TOF GWAS. - Additional suggestive loci at 10p11, 10p14, 15q13, 16q12. - A common PTPN11 variant contributes to TOF risk in Europeans. - In Chinese cohorts, rs2228638 in NRP1 (10p11) significantly increased TOF risk (OR=1.52, 95% CI 1.13–2.04, P=0.006) (PMID:24594544). - Among 22q11.2 deletion carriers, a modifier GWAS identified rs12519770 in GPR98 (ADGRV1) at 5q14.3 (P=2.98×10⁻⁸) as associated with TOF risk specifically within the deletion population (PMID:29025761).

Recurrence risk (empirical/genetic-counseling estimates, PMC12940485): - Sporadic non-syndromic TOF, no identified genetic cause: ~2–5% sibling recurrence risk (consistent with the classically cited 1–5% figure). - Autosomal dominant monogenic cause identified (NOTCH1, FLT4, NKX2-5, GATA6): up to 50% theoretical recurrence, tempered by incomplete/variable penetrance. - Chromosomal syndromes (22q11.2 deletion, trisomy 21): typically <1% recurrence unless a parent carries a balanced structural rearrangement or is a mosaic/germline carrier.

Environmental Risk Factors

  • Maternal pregestational diabetes mellitus — meta-analyses show an increased odds ratio of approximately 3–5 for TOF in offspring; hyperglycemia is teratogenic during first-trimester cardiogenesis and alters embryonic retinoic acid catabolism (PMC10449132).
  • Retinoic acid/isotretinoin exposure — a potent teratogen linked to conotruncal anomalies via interference with cardiac neural crest cell migration.
  • Maternal phenylketonuria (PKU) with poor metabolic control.
  • Congenital rubella infection.
  • Advanced maternal age (>40 years) has been reported as a risk factor.
  • Fetal alcohol exposure and maternal warfarin use — associated teratogens, though effect sizes for TOF specifically are less robustly quantified than for diabetes/retinoic acid.
  • Family history of CHD, or parental history of TOF/22q11.2DS.

Protective Factors

  • Periconceptional folic acid / multivitamin supplementation is the best-documented protective/preventive factor:
  • A Hungarian cohort study (1980–1996) found high-dose folic acid users (mean 5.6 mg/day) had significantly reduced TOF risk, OR 0.53 ([search synthesis, cites Czeizel-type Hungarian intervention data]).
  • A Netherlands registry-based case-control study found periconceptional folic acid use associated with an overall reduction in CHD risk (PMID:19952004).
  • Broader meta-analytic estimates: periconceptional folic acid use associated with ~20% reduction in prevalence of any CHD, and up to 59% reduction in critical CHD in some cohort analyses; protection is greater when supplementation begins before conception.
  • No specific genetic protective variants for TOF have been robustly established in the literature reviewed (in contrast to well-characterized protective alleles in other polygenic diseases); this is a knowledge gap.

Gene-Environment Interactions

The 2025/2026 genetics-epigenetics review frames TOF as arising from "convergence of multiple disrupted developmental pathways — Notch, VEGF, and SHF–neural crest signaling — rather than single-gene defects" (PMC12940485). Maternal hyperglycemia has been mechanistically linked to altered embryonic retinoic acid catabolism, suggesting a shared final pathway between the diabetes and retinoic-acid teratogenic routes (PMC10449132). Postnatally, mitochondrial dysfunction and chronic hypoxia interact with genetic background — FOXO1 is proposed to "act as a metabolic stress sensor" mediating postnatal right-ventricular cardiomyocyte vulnerability in unrepaired/palliated TOF (PMC12940485).

3. Phenotypes

Cardinal anatomic/clinical features

Phenotype HPO term (suggested) Frequency Notes
Ventricular septal defect (malalignment-type) HP:0001629 Obligate (100%) Perimembranous, non-restrictive; may extend to muscular septum
Overriding aorta HP:0002623 Obligate (100%) Aortic valve annulus straddles the VSD
Right ventricular outflow tract obstruction / pulmonic stenosis HP:0001642 (Pulmonic stenosis); HP:0004415 (infundibular pulmonic stenosis) Obligate (100%), severity variable Infundibular, valvar, supravalvar, or branch PA stenosis, singly or combined
Right ventricular hypertrophy HP:0001714 Obligate (secondary) Compensatory, develops post-natally
Cyanosis HP:0000961 Variable — from birth to adulthood depending on RVOT obstruction severity "Pink" (acyanotic) TOF possible with mild obstruction
Hypercyanotic ("Tet") spells (no precise single HPO term; consider HP:0000961 + episodic qualifier) Common in infancy, especially 2–4 months See mechanism below
Clubbing (digital) HP:0100759 Common with chronic cyanosis Late finding
Systolic ejection murmur (RVOT) HP:0031264 (Heart murmur) Nearly universal Harsh, left upper sternal border
Squatting behavior (older children) — Historic, less seen with early surgical repair Increases SVR, reduces right-to-left shunt
Failure to thrive HP:0001508 Variable Seen in significant cyanosis/heart failure
Boot-shaped heart ("coeur en sabot") on chest radiograph HP:0004943 (if applicable) Classic imaging finding Due to RVH and diminished main PA segment

Associated coronary and vascular anomalies

  • Coronary artery anomalies: ~5–6% of TOF patients, most commonly the left anterior descending (LAD) arising from the right coronary artery (RCA) and crossing the RVOT — surgically important because a transannular ventriculotomy can jeopardize this vessel (PMC7599042; International Journal of Cardiology meta-analysis). Combined risk of anomalous coronary artery or large conal branch crossing the RVOT: ~10.3%.
  • Right-sided aortic arch: ~25% of all TOF, much higher (up to 24–48%) in 22q11.2DS-associated cases.
  • MAPCAs (major aortopulmonary collateral arteries): prominent in TOF with pulmonary atresia, providing alternate pulmonary blood supply when central pulmonary arteries are hypoplastic/atretic.
  • Patent foramen ovale/ASD ("pentalogy of Fallot" when present).

Phenotype characteristics

  • Age of onset: Congenital (present from birth); cardiac malformation completes during weeks 3–8 of gestation. Clinical cyanosis may be present at birth (severe RVOT obstruction) or emerge over the first weeks to months of life as infundibular obstruction (dynamic, muscular) progresses.
  • Severity: Highly variable, forming a spectrum from "pink TOF" (mild RVOT obstruction, net left-to-right shunt) to TOF with pulmonary atresia (ductal- or MAPCA-dependent pulmonary blood flow, most severe).
  • Progression: The infundibular (muscular) component of RVOT obstruction is dynamic and can worsen over the first months of life due to progressive infundibular hypertrophy, precipitating hypercyanotic spells.
  • Frequency of hypercyanotic spells: Peak incidence around 2–4 months of age; can occur in unrepaired or palliated patients.

Hypercyanotic ("Tet") spell mechanism

Spells result from an acute imbalance between pulmonary and systemic vascular resistance, causing decreased pulmonary blood flow and increased right-to-left shunting; infundibular spasm can contribute but "is not required for these spells to occur" (PMID:1428277; Starship guidelines). A self-perpetuating cycle involves hypoxemia, metabolic acidosis, hyperpnea, increased systemic venous return, and catecholamine-driven pulmonary vasoconstriction. Common triggers: crying/distress, defecation/straining, feeding, waking from sleep (low SVR), fever, dehydration, tachycardia/tachypnea from any cause, and some medications (e.g., ACE inhibitors). Treatment: knee-chest positioning, supplemental oxygen, volume expansion (non-pharmacologic first-line); beta-blockade to reduce infundibular spasm and alpha-1 agonists to raise SVR for refractory spells.

Long-term/late phenotypes (post-repair)

  • Chronic pulmonary regurgitation — the dominant late residual lesion after transannular-patch repair, driving progressive RV dilation/dysfunction.
  • Arrhythmias — ~43% of patients develop supraventricular or ventricular arrhythmias during long-term follow-up; QRS prolongation is a marker of RV dilation and arrhythmic risk.
  • Sudden cardiac death — incidence ~1.8% at 8-year follow-up in some cohorts; overall ~10% of late deaths in repaired-TOF populations are attributed to sudden death, probably arrhythmic.
  • Heart failure — ~40% of late deaths in repaired-TOF (rTOF) populations attributed to heart failure.

Neurodevelopmental/cognitive phenotypes

Adolescents/adults with repaired TOF show neurocognitive deficits in executive function, visuospatial skills, memory, attention, academic achievement, social cognition, and problem-solving, alongside increased prevalence of anxiety disorders, disruptive behavior, and ADHD, despite normal IQ (PMC8870281).

Quality of life impact

Health-related quality of life in adults with repaired TOF is generally satisfactory but with residual psychosocial and cognitive problems. Better NYHA class, >3 hours/week physical activity, and preserved RV function are positively associated with QoL (PMC6443137). Exercise capacity is measurably reduced at a group level (mean ~74.8% predicted workload in a cohort of 314 adults), though most patients remain NYHA class I.

4. Genetic/Molecular Information

Causal genes (summary table)

Gene HGNC OMIM Role % of TOF (approx.) Variant type
NOTCH1 HGNC:7881 *190198 Notch signaling receptor ~4.5% (non-syndromic) Predominantly missense; some LOF/in-frame indel
FLT4 (VEGFR3) HGNC:3767 *136352 VEGF-C receptor, lymphatic/vascular signaling ~2.4% Predominantly loss-of-function; splice-site variants also reported
NKX2-5 HGNC:2488 *600584 Cardiac homeobox transcription factor ≥4% Non-homeodomain missense in TOF (contrast with classic homeodomain mutations in ASD/AV block)
JAG1 HGNC:6188 *601920 Notch ligand (Alagille syndrome gene) 1–2% Various — haploinsufficiency
GATA4 HGNC:4173 *600576 Zinc-finger cardiac transcription factor Minority Haploinsufficiency
TBX1 HGNC:11592 *602054 T-box transcription factor, 22q11.2 critical gene Contained within 22q11.2 deletion (~15% of TOF) Deletion/haploinsufficiency (rarely point mutation)
TBX5 HGNC:11602 *601620 T-box transcription factor (Holt-Oram) Minority —
ZFPM2 (FOG2) HGNC:19091 *603693 GATA cofactor Minority —
PTPN11 HGNC:9644 *176876 RAS/MAPK pathway phosphatase (Noonan syndrome) Minority; also a common-variant GWAS hit —

Variant classification / population frequency: Pathogenicity is assessed per ACMG/AMP guidelines via ClinVar/ClinGen; allele frequency filtering against gnomAD is standard practice in TOF exome studies to prioritize ultra-rare/de novo damaging variants. De novo damaging variants in TOF probands are enriched in genes whose expression is spatially restricted to the myogenic progenitors of the outflow tract, based on integration with single-cell/spatial transcriptomic atlases of early human heart development (PMID:34905512).

Somatic vs. germline: TOF-causing variants are essentially all germline (developmental disorder); no somatic mosaicism literature of note was identified in this search.

Functional consequences: Mixed — loss-of-function (FLT4, most JAG1, GATA4 haploinsufficiency), missense/gain- or loss-of-function depending on domain (NOTCH1), and dosage-sensitivity (TBX1 within 22q11.2 deletion; NKX2-5).

Diagnostic yield of sequencing

  • Whole-exome sequencing (WES) of clinical cohorts with non-isolated TOF (TOF+ extracardiac features) yields a definitive/probable molecular diagnosis in 23.6% of patients (31/131 individuals) (EJHG 2025, PMC/non-isolated TOF exome study).
  • In non-syndromic cohorts, the combined NOTCH1+FLT4 yield is ~7%, rising to ~15–16% across nine candidate genes.

Epigenetic information

From DNA methylation and microRNA studies of TOF myocardium/right ventricular outflow tract tissue (PMC12940485; also see DNA methylation study PMC3819647): - Hypermethylation of NKX2-5, HAND1, and GATA4 promoter regions is reported to "repress their expression, leading to impaired cardiomyocyte differentiation." - Hypomethylation of VEGFA and FLT4 suggests "compensatory activation of vascular remodeling pathways." - MicroRNA dysregulation: downregulation of miR-1 and miR-133 disrupts HAND2 and GJA1 (connexin-43) expression; dysregulated miR-424 and miR-222 "modulate endothelial and smooth muscle cell differentiation within the outflow tract." - Histone modification: TBX1 haploinsufficiency has been linked to promotion of histone deacetylation at the MEF2C enhancer, reducing H3 acetylation and silencing MEF2C — a proposed mechanism connecting the 22q11.2 deletion to downstream cardiac transcriptional dysregulation.

Chromosomal abnormalities

  • 22q11.2 microdeletion (typically 1.5–3 Mb, encompassing TBX1, DGCR8, CRKL, MAPK1, and dozens of other genes) — detected by FISH, chromosomal microarray, or MLPA; the most common structural genetic finding in TOF (~15%).
  • Trisomy 21, 18, 13.
  • Genome-wide microarray/chromosomal microarray analysis (CMA) is recommended as the first-line clinical genetic test for TOF across the lifespan, given it captures the 22q11.2 microdeletion and other pathogenic CNVs.

5. Environmental Information

Environmental (teratogenic) factors

  • Maternal hyperglycemia/pregestational diabetes — most robustly evidenced teratogenic exposure (OR ~3–5); mechanistically linked to altered embryonic retinoic acid catabolism under a diabetic milieu (PMC10449132, model-organism/embryo evidence).
  • Retinoic acid derivatives (isotretinoin) — interferes with cardiac neural crest cell migration essential for outflow tract septation.
  • Maternal phenylketonuria with poor dietary control during pregnancy.
  • Warfarin exposure in utero.
  • Fetal alcohol exposure.

Lifestyle factors

No CHD-specific lifestyle risk factor beyond the above (e.g., maternal smoking data for TOF specifically were not surfaced with strong effect sizes in this search; general CHD literature implicates maternal smoking and obesity for CHD broadly but TOF-specific quantification is a gap).

Infectious agents

  • Congenital rubella infection — classically associated with a spectrum of CHD, including TOF, as part of congenital rubella syndrome, though PDA and pulmonary artery stenosis are more classically rubella-associated; TOF association is reported but less specific than for other lesions.

6. Mechanism / Pathophysiology

Embryologic/causal chain

  1. Trigger: Genetic lesion (e.g., NOTCH1, FLT4, NKX2-5, TBX1 haploinsufficiency in 22q11.2DS) or environmental teratogenic insult (maternal hyperglycemia, retinoic acid) disrupts second heart field (SHF) progenitor addition and/or cardiac neural crest cell (CNCC) migration into the developing outflow tract during weeks 3–8 of gestation.
  2. Cellular process: TBX1 is required for efficient incorporation of SHF cardiac progenitors into the heart; "loss of TBX1 impairs extracellular matrix (ECM)-integrin-focal adhesion (FA) signaling," non-cell-autonomously impairing progenitor cell migration ([Circ Res, PMID for Tbx1/SHF mechanism]). Neural-crest-derived NEDD4 controls DKK1 protein levels, modulating Wnt signaling in the SHF to balance progenitor maintenance vs. myocardial differentiation (mouse model + human variant evidence, bioRxiv/PMC12913648). GATA4 drives Hedgehog (Hh) signaling required for SHF migration and outflow tract development; decreased Gata4 expression in mice produces double-outlet right ventricle and hypoplastic ventricular myocardium.
  3. Anatomic result — infundibular septal malalignment: Anterocephalad (superior/leftward) deviation of the infundibular (outlet) septum relative to the muscular ventricular septum prevents normal ventricular septal closure, producing the four cardinal TOF features as a single unified defect (StatPearls; ScienceDirect CHD review):
  4. The malaligned septum leaves a large VSD.
  5. The aortic root, no longer aligned over the LV outflow, overrides the VSD.
  6. Hypoplasia of the subpulmonary infundibulum narrows the RVOT, producing obstruction at infundibular, valvar, and/or supravalvar/branch-PA levels.
  7. The RV, ejecting against elevated afterload (systemic-level pressure via the VSD and RVOT obstruction), undergoes secondary hypertrophy.
  8. Physiologic consequence: The degree of RVOT obstruction determines shunt direction and clinical severity — mild obstruction yields "pink" TOF with left-to-right (or balanced) shunting; severe/complete obstruction (pulmonary atresia) makes pulmonary blood flow duct- or MAPCA-dependent with obligate right-to-left shunting and cyanosis.
  9. Postnatal remodeling: Chronic cyanosis and RV pressure/volume overload drive compensatory polycythemia, RVH, and later — post-repair — chronic pulmonary regurgitation-driven RV dilation, fibrosis, and arrhythmogenic substrate formation. Postnatal RV cardiomyocytes under chronic hypoxic/metabolic stress show mitochondrial dysfunction, with FOXO1 proposed as a metabolic-stress sensor mediating cardiomyocyte vulnerability (PMC12940485).

Molecular pathways

  • Notch signaling (NOTCH1, JAG1) — outflow tract septation and cardiac neural crest/endocardial cushion signaling.
  • VEGF/VEGFR signaling (FLT4/VEGFR3, VEGFA) — vascular and outflow tract endothelial-to-mesenchymal transition.
  • RAS-MAPK pathway (PTPN11) — overlapping with RASopathy (Noonan syndrome) cardiac phenotypes.
  • Wnt signaling (via NEDD4-DKK1 axis) — SHF progenitor balance.
  • Hedgehog signaling (via GATA4) — SHF migration.
  • Suggested GO terms: GO:0003151 (outflow tract morphogenesis), GO:0003148 (outflow tract septum morphogenesis), GO:0003208 (cardiac ventricle morphogenesis), GO:0061308 (cardiac neural crest cell development involved in outflow tract morphogenesis), GO:0055010 (ventricular cardiac muscle tissue morphogenesis) — verify canonical labels via OAK before curation.

Cellular processes/cell types involved

  • Second heart field (SHF) cardiac progenitor cells — anterior/posterior SHF contributes to right ventricle and outflow tract myocardium.
  • Cardiac neural crest cells (CNCC) — migrate into the outflow tract cushions to pattern the aorticopulmonary septum.
  • Endocardial cushion mesenchyme (endothelial-to-mesenchymal transition).
  • Cardiomyocytes of the RV and outflow tract myocardium (hypertrophy, later fibrosis).
  • Suggested CL terms: CL:0002079 (cardiac neural crest cell), CL:0000746 (cardiac muscle cell), CL:0002350 (endocardial cell) — verify via OAK.

Molecular profiling (recent single-cell/transcriptomic findings)

  • Integration of single-cell and spatial transcriptomics of early human heart development (6.5–7.0 post-conceptional weeks) with TOF exome data shows that genes carrying damaging de novo mutations in TOF probands are significantly enriched in myogenic progenitors of the cardiac outflow tract and show "significant spatial expression in outflow tract or great vessels, consistent with the anatomic defect in TOF" (PMID:34905512, JCI Insight, human clinical + computational).
  • A single-cell RNA-seq study of fetal TOF hearts identified 15 cell-type clusters with differential expression in atrial/ventricular cardiomyocytes enriched for damaging mutations (PMID:39097963).
  • A 2026 integrative bulk + single-nucleus transcriptomic study of non-syndromic TOF RVOT tissue found proteostasis- and metabolism-related alterations (Functional & Integrative Genomics, 2026).
  • A maternal-fetal microRNA axis has been proposed as a mechanistic and potential biomarker link in TOF (Frontiers in Cardiovascular Medicine, 2026).

7. Anatomical Structures Affected

Organ level

  • Primary organ: Heart — specifically the right ventricular outflow tract/infundibulum, pulmonary valve/main and branch pulmonary arteries, interventricular septum, and aortic root.
  • Secondary/complication-related involvement: Lungs (pulmonary blood flow abnormalities, MAPCAs), liver/spleen (chronic cyanosis, polycythemia sequelae historically), CNS (neurodevelopmental effects, and historically brain abscess/paradoxical embolism risk in unrepaired cyanotic patients), skeletal system in syndromic forms (e.g., VACTERL vertebral anomalies).
  • Body system: Primarily cardiovascular; secondarily can be part of multisystem syndromes (craniofacial/thymic/parathyroid in 22q11.2DS; hepatic/vertebral/ocular in Alagille syndrome).

Tissue and cell level

  • Myocardium of the RV outflow tract/infundibulum (hypertrophied, later fibrotic post-repair).
  • Endocardial cushion-derived valve tissue (pulmonary valve — dysplastic or absent in APVS).
  • Vascular smooth muscle and endothelium of the pulmonary arteries (hypoplasia, or dilation in APVS).
  • Suggested Cell Ontology terms as above (cardiac muscle cell, cardiac neural crest cell, endocardial cell).

Subcellular level

  • Mitochondrial dysfunction implicated in chronically hypoxic/stressed RV cardiomyocytes (GO Cellular Component: GO:0005739 mitochondrion).
  • Sarcomeric/cytoskeletal remodeling in hypertrophied RV myocytes.

Localization

  • Bilateral/central structure (the heart itself is midline, but lesion components are RV/RVOT-lateralized — i.e., right-sided obstruction with left-to-right positioned aortic override).
  • Suggested UBERON terms: UBERON:0002080 (right cardiac ventricle), UBERON:0002094 (outflow tract, verify exact ID), interventricular septum, pulmonary trunk/pulmonary valve, aortic root — verify canonical IDs via OAK before curation.

8. Temporal Development

Onset

  • Congenital — the anatomic malformation is established during weeks 3–8 of embryogenesis (cardiogenesis).
  • Clinical onset of cyanosis: variable — present at birth in severe RVOT obstruction/pulmonary atresia (ductal-dependent), or emerging over the first days to months of life as the dynamic infundibular component of obstruction progresses. "Pink" TOF (minimal cyanosis) is possible with milder obstruction.
  • Onset pattern: typically acute-to-subacute recognition in the neonatal period via cyanosis, murmur, or prenatal diagnosis; occasionally insidious presentation in older infants/children with milder forms ("pink Fallot").

Progression

  • Natural history (unrepaired): Without surgical intervention, historical data (pre-surgical era) showed high mortality — approximately 25% mortality by 1 year, 40% by age 3, 70% by age 10, and only ~5% survival to age 40 in unrepaired disease (classical natural-history literature; note this reflects an older evidence base predating modern surgical care).
  • Post-repair progression: Early survival is now excellent (see Section 11), but a well-characterized late progression pattern exists: residual/progressive pulmonary regurgitation → RV dilation → RV dysfunction → arrhythmia risk → (in a minority) heart failure or sudden death, typically emerging in the second to fourth decades of life. "About 75% of infants who undergo repair during infancy will survive to reach their second to third decade of life without major consequences; however, after the first two decades of life, symptoms start to appear due to pulmonary valve regurgitation, and by the fourth decade of life, most survivors are symptomatic."
  • Disease course pattern: Largely stable-to-slowly-progressive after successful repair, punctuated by discrete reintervention events (pulmonary valve replacement) rather than continuous decline; a minority experience arrhythmic events.

Patterns

  • Remission: Surgical repair is curative for the anatomic shunt physiology but not for the RVOT/pulmonary valve — this is a "residual lesion" disease model rather than a remitting-relapsing one.
  • Critical periods: (1) Weeks 3–8 gestation — the teratogenic/genetic vulnerability window for the primary malformation; (2) Infancy (particularly 2–4 months) — peak vulnerability window for hypercyanotic spells due to dynamic infundibular hypertrophy; (3) Timing of surgical intervention (see Section 12) is itself a "critical period" concept, balancing risks of early repair against benefits of allowing pulmonary annulus growth via staged palliation.

9. Inheritance and Population

Epidemiology

  • Prevalence/incidence: TOF occurs in approximately 30–60 per 100,000 births (~3 per 10,000 live births); it represents 5–7% (some sources cite 5–10%) of all congenital heart defects, and is the most common cyanotic CHD. Congenital heart defects overall affect ~1% of newborns worldwide. One source cites incidence of ~0.326 per 1,000 live births.
  • Geographic variation: Prevalence appears considerably higher in Sub-Saharan Africa relative to global estimates and reports from developed countries (systematic review/meta-analysis, PLOS ONE), likely reflecting a combination of true prevalence differences, case-ascertainment/survival differences, and healthcare-access factors relevant to CHD registries.

Inheritance pattern

Orphanet classifies TOF inheritance as "Autosomal dominant" and "Multigenic/multifactorial" (i.e., most cases are multifactorial/sporadic, but a genetic subset — when a single dominant pathogenic variant is identified, e.g., NOTCH1, NKX2-5 — follows autosomal dominant inheritance with variable/incomplete penetrance).

  • Penetrance: Incomplete for most identified monogenic causes (e.g., NKX2-5 variants in TOF are "not fully penetrant" [Circulation, hc4601.098427]; FLT4 splice-site variants show "incomplete penetrance" [EJHG 2025 study]).
  • Expressivity: Variable — the same genetic lesion (e.g., 22q11.2 deletion) can produce a spectrum of conotruncal defects (TOF, interrupted aortic arch, truncus arteriosus, isolated VSD) even within families.
  • Genetic anticipation: Not a recognized feature of TOF (not a repeat-expansion disorder).
  • Germline mosaicism: Not specifically well-characterized for TOF in this search — plausible for recurrence in families without an affected parent but not quantified in the literature surveyed (gap).
  • Founder effects: Not prominently reported for TOF (contrast with some other Mendelian conditions); population-specific common variants (e.g., NRP1 rs2228638 in Chinese cohorts) suggest population-differentiated susceptibility-allele frequencies rather than classical founder mutations.
  • Consanguinity: Autosomal recessive inheritance is documented in the Keeshond dog model (see Section 14) but is not the predominant human inheritance pattern; consanguinity's role in human non-syndromic TOF is not strongly quantified in this search.
  • Sibling recurrence risk: ~1–5% for sporadic non-syndromic TOF (see Section 2).

Population demographics

  • Sex ratio: Not sharply skewed in the general literature reviewed (in contrast to some other CHDs); specific TOF male:female ratio data were not strongly surfaced in this search (gap — commonly cited informally as roughly equal or slight male predominance; should be verified against a registry source before curation).
  • Age distribution: Diagnosed at any age given prenatal detection, neonatal screening, and, in low-resource settings, later childhood/adult presentation of unrepaired or palliated disease ("longstanding unrepaired TOF" is a recognized adult clinical entity, PMC9508357).
  • Syndromic subpopulations: 22q11.2DS (~15% of TOF), trisomy 21 (~7% of TOF), Alagille syndrome (1–2%).

10. Diagnostics

Clinical tests

  • Physical examination: Cyanosis (variable), harsh systolic ejection murmur at the left upper sternal border (RVOT obstruction), single S2 (absent/soft pulmonic component), clubbing in chronic cyanosis.
  • Pulse oximetry screening (universal newborn CCHD screening): a cutoff of <90% SpO2 (or the standard <95% + differential limb algorithm used broadly) shows in one analysis 90% sensitivity, 99.94% specificity, 75% PPV, 99.98% NPV for detecting critical CHD; optimal screening window is 8–24 hours of life. TOF is one of the seven CDC-defined "critical congenital heart disease" (CCHD) lesions targeted by this screening (alongside hypoplastic left heart syndrome, pulmonary atresia with intact septum, TAPVR, transposition of the great arteries, tricuspid atresia, truncus arteriosus).
  • Chest radiograph: classic "boot-shaped heart" (coeur en sabot) from RVH and diminished main PA segment; decreased pulmonary vascular markings.
  • Electrocardiography: right axis deviation, RVH pattern.
  • Echocardiography (transthoracic): primary, first-line diagnostic modality — delineates VSD, aortic override, RVOT obstruction level/severity, pulmonary annulus/branch PA size (z-scores), and screens for associated coronary anomalies.
  • Cardiac CT angiography / cardiac catheterization / angiography: used pre-operatively, especially to define coronary artery anatomy (LAD-from-RCA), MAPCAs, and branch PA anatomy in complex/pulmonary-atresia variants.
  • Cardiac MRI: central to adult/post-repair surveillance — quantifies RV volumes, pulmonary regurgitant fraction, and guides timing of pulmonary valve replacement.

Prenatal/fetal diagnosis

  • Fetal echocardiography is the standard prenatal screening/diagnostic method in high-income countries; more than 50% of critical CHD cases are now prenatally detected in such settings.

Genetic testing

  • Chromosomal microarray (CMA) is recommended as the first-line clinical genetic test for TOF across the lifespan (captures 22q11.2 microdeletion and other pathogenic CNVs).
  • FISH for targeted 22q11.2 deletion confirmation.
  • Karyotyping for suspected aneuploidy (trisomy 21/18/13).
  • Gene panels / whole-exome sequencing (WES) recommended for isolated (non-syndromic) TOF or when CMA is non-diagnostic, particularly for non-isolated TOF (TOF+ extracardiac anomalies), where WES yields a definitive/probable diagnosis in ~23.6% of cases.
  • Whole-genome sequencing (WGS) increasingly used in research cohorts (e.g., ultra-rare variant burden analysis across 231 genome sequences).

Clinical/diagnostic criteria

No formal DSM/ICD-style diagnostic-criteria checklist exists beyond echocardiographic/anatomic confirmation of the four cardinal features (or their pulmonary-atresia/APVS variant equivalents). Differential diagnosis includes other conotruncal defects (double-outlet right ventricle, truncus arteriosus, transposition of the great arteries with VSD and pulmonary stenosis, isolated pulmonary atresia with VSD) which share overlapping embryology and can present similarly on initial imaging.

Screening

  • Newborn pulse oximetry screening — universal in most high-income health systems, part of standard CCHD screening panels.
  • Prenatal ultrasound anomaly scanning — routine anatomy scan (typically ~18–22 weeks) with cardiac views; fetal echocardiography for higher-risk pregnancies or suspicious anatomy-scan findings.
  • Cascade/family genetic screening when a pathogenic monogenic variant or 22q11.2 deletion is identified in a proband, given autosomal dominant inheritance patterns for identified single-gene causes.

11. Outcome/Prognosis

Survival

  • Modern surgical era, long-term survival after complete repair:
  • 97.7% at 10 years and 94.5% at 30 years in one large series; another source reports ~95% at 10 years and 90% at 15 years.
  • A landmark long-term follow-up (36-year, 490 survivors of the first postoperative year) found 32-year actuarial survival of 86%, versus an expected 96% in an age/sex-matched general population (PMID:9350942).
  • Very long-term (50-year) follow-up: survival at 50 years post-repair is 71% overall (84% among in-hospital survivors), but event-free survival is only 9% — reintervention occurs in ~40%, supraventricular arrhythmia in ~18%, and ventricular tachycardia in ~7% (PMID:39870118).
  • Independent predictors of long-term survival: older age at operation, and a higher postoperative RV:LV systolic pressure ratio (worse outcome) (NEJM 1993, PMID via NEJM199308263290901). Genetic abnormalities (e.g., 22q11.2DS) are associated with increased mortality risk in both early and late postsurgical phases.
  • Unrepaired natural history (historical, pre-surgical-era data): substantial early mortality, with only a small minority surviving to adulthood without intervention.

Morbidity and function

  • ~43% of repaired-TOF patients develop supraventricular or ventricular arrhythmias on long-term follow-up.
  • Sudden cardiac death: incidence ~1.8% at 8-year follow-up in one cohort; ~10% of late deaths in rTOF populations attributed to sudden (likely arrhythmic) death; ~40% of late deaths attributed to heart failure.
  • Exercise capacity is reduced at a group level (mean ~74.8% of predicted workload in one 314-patient adult cohort), though most patients remain functionally NYHA class I.
  • Neurodevelopmental morbidity: deficits in executive function, visuospatial skills, memory, attention, academic achievement, and social cognition; increased anxiety, disruptive behavior disorders, and ADHD prevalence, persisting into adulthood and affecting employment/social adjustment (PMC8870281; PMC11082288).
  • Quality of life: generally satisfactory in repaired-TOF adults, with better QoL linked to NYHA class I status, greater physical activity, and preserved RV function; weight extremes (underweight or obesity) negatively affect QoL in children with TOF variants (PMC11787155).

Complications

  • Chronic pulmonary regurgitation → RV dilation/dysfunction (the dominant late complication driving reintervention).
  • Residual/recurrent RVOT obstruction (valvar, subvalvar, or branch PA).
  • Residual VSD.
  • Aortic root dilation (late, in some cohorts).
  • Endocarditis risk (as with any residual structural heart disease/prosthetic material).
  • Reintervention burden: transannular-patch repair cohorts show increased procedural burden at 25 years compared to valve-sparing repair strategies.

Prognostic factors and biomarkers

  • Age at operation, postoperative RV:LV pressure ratio, presence of a genetic syndrome (particularly 22q11.2DS), QRS duration/prolongation (arrhythmia risk marker), degree of pulmonary regurgitation and RV dilation on cardiac MRI (guides timing of pulmonary valve replacement), and type of repair (transannular patch vs. valve-sparing) are the principal prognostic determinants identified in this literature.

12. Treatment

Surgical/interventional (definitive management)

  • Complete surgical repair — the mainstay of treatment: closure of the VSD with a patch, and relief of RVOT obstruction (resection of infundibular muscle, ± transannular patch across the pulmonary annulus, ± valve-sparing/pulmonary-valve-preserving techniques when annulus size permits). Suggested NCIT term: NCIT:C15329 (Surgical Procedure) — verify specific TOF-repair NCIT/procedure code if a more precise term exists.
  • Staged palliation (for symptomatic/ductal-dependent or high-risk neonates/young infants):
  • Modified Blalock-Taussig-Thomas (BTT) shunt — surgical systemic-to-pulmonary shunt, historically the standard initial palliative procedure, allows pulmonary annulus/branch PA growth before complete repair, reducing need for transannular incision.
  • RVOT stenting and arterial ductal stenting — transcatheter alternatives to surgical shunting for initial palliation; comparative studies show RVOT-stented infants were palliated at a younger age (mean 1.62 ± 0.34 months) versus modified BT shunt (2.80 ± 0.52 months).
  • Indications for palliation over primary repair: low birth weight, small pulmonary arteries, complex/high-risk anatomy.
  • Balloon pulmonary valvuloplasty — used in select cases as a bridging/palliative catheter intervention.
  • Pulmonary valve replacement (PVR) — the principal late reintervention for symptomatic or hemodynamically significant chronic pulmonary regurgitation after repair; may be surgical or transcatheter (percutaneous pulmonary valve implantation). PVR improves symptoms and can reduce ventricular tachycardia incidence (one study: 22% → 9% at mean 4.7-year follow-up post-PVR) but does not reliably reverse other deleterious effects, and current guidelines do not consider ventricular arrhythmia risk alone a sufficient indication for PVR given lack of robust evidence that PVR reduces subsequent ventricular arrhythmia risk.

Pharmacotherapy

  • Beta-blockers (e.g., propranolol) — reduce infundibular spasm/hypercyanotic spell frequency, used both acutely for spells and as chronic prophylaxis in some unrepaired/palliated infants.
  • Alpha-1 agonists (e.g., phenylephrine) — increase systemic vascular resistance to acutely terminate hypercyanotic spells.
  • Prostaglandin E1 (alprostadil) — maintains ductal patency in ductal-dependent pulmonary blood flow (severe RVOT obstruction/pulmonary atresia) pending intervention.
  • Diuretics/afterload-reducing agents — supportive management of heart failure symptoms in decompensated repaired-TOF patients.
  • Antiarrhythmic medications — for management of supraventricular/ventricular arrhythmias in the long-term follow-up population.
  • Disopyramide — reported in case literature (e.g., a 72-year-old awaiting primary TOF repair) for tet-spell management as an alternative agent.

Supportive/rehabilitative

  • Non-pharmacologic hypercyanotic spell management: knee-chest positioning, supplemental oxygen, IV volume expansion.
  • Genetic counseling — particularly relevant given autosomal dominant inheritance patterns of identified monogenic causes and the ~15% 22q11.2DS association (NCIT:C15240, Genetic Counseling).
  • Multidisciplinary neurodevelopmental follow-up/early intervention for at-risk repaired-TOF children (given the well-documented cognitive/behavioral morbidity profile).
  • Cardiac rehabilitation/structured exercise programs to address measurable exercise-capacity deficits in adults.

Device/electrophysiologic therapies

  • Implantable cardioverter-defibrillator (ICD) placement — for selected high-risk patients based on arrhythmia risk stratification (QRS duration, RV dilation/dysfunction, inducible VT, prior sustained VT/aborted SCD).
  • Catheter ablation of atrial or ventricular arrhythmia substrate in symptomatic late-postoperative patients.

Experimental/emerging

  • Ongoing clinical trials comparing early versus later re-valving (PVR) strategy in TOF with free pulmonary regurgitation (e.g., trial protocol referenced at NCT04084132).
  • Research-stage work on microRNA-based biomarkers (maternal-fetal microRNA axis) for risk stratification, and integrative multi-omics (bulk + single-nucleus transcriptomics of RVOT tissue) toward mechanistic/biomarker discovery — not yet clinical-grade diagnostics or therapeutics.

Treatment algorithm summary

Neonatal/infant presentation → assess ductal dependency and anatomic risk factors → primary complete repair (if anatomy/size favorable) or staged palliation (BT shunt / RVOT or ductal stent) followed by complete repair later in infancy → long-term surveillance (echocardiography, cardiac MRI) for pulmonary regurgitation/RV dilation → pulmonary valve replacement when criteria met → arrhythmia risk stratification and, where indicated, ICD/ablation → lifelong adult congenital heart disease (ACHD) specialty follow-up.

13. Prevention

Primary prevention

  • Periconceptional folic acid/multivitamin supplementation, ideally initiated before conception, is the best-evidenced modifiable primary-prevention strategy, with reported risk reductions specifically for TOF (OR ~0.53 in a Hungarian cohort) and for CHD broadly (~20–59% reduction depending on cohort/definition) (see Section 2).
  • Optimization of maternal glycemic control prior to and during early pregnancy in women with pregestational diabetes — directly targets the most robustly quantified modifiable teratogenic risk factor (OR ~3–5 reduction target).
  • Avoidance of retinoic acid/isotretinoin exposure during the periconceptional period and pregnancy.
  • Rubella immunization prior to pregnancy (standard public health measure, reduces congenital rubella syndrome-associated CHD broadly).
  • Genetic counseling and family planning guidance for known carriers of monogenic TOF-associated variants or 22q11.2 deletion, given autosomal dominant transmission with variable penetrance.

Secondary prevention (early detection)

  • Newborn pulse oximetry screening — a low-cost, high-specificity universal screening tool for critical CHD including TOF, recommended for all newborns at 8–24 hours of life.
  • Fetal anomaly ultrasound screening with referral to fetal echocardiography when cardiac views are abnormal or risk factors are present (family history, pregestational diabetes, teratogen exposure).
  • Prenatal genetic screening (e.g., non-invasive prenatal testing, or targeted testing when a fetal cardiac anomaly suggestive of a conotruncal defect is found) to identify 22q11.2 deletion or trisomy, informing prenatal counseling and delivery planning.

Tertiary prevention (preventing complications in affected individuals)

  • Structured lifelong ACHD (adult congenital heart disease) follow-up protocols, including serial cardiac MRI for pulmonary regurgitant fraction/RV volumetric surveillance, to enable timely pulmonary valve replacement before irreversible RV dysfunction develops.
  • Arrhythmia risk-stratification programs (QRS duration monitoring, Holter surveillance) to guide prophylactic ICD placement in appropriately selected patients.
  • Infective endocarditis prophylaxis per standard congenital heart disease guidelines for at-risk repaired patients (prosthetic material, residual shunts).
  • Structured neurodevelopmental screening and early intervention referral for repaired-TOF children, given the well-documented cognitive/behavioral risk profile.

Public health / population-level

  • Population folic acid fortification programs (mandatory grain fortification in many countries) are credited with reduction in neural tube defects and have shown associated reductions in some CHD categories, including conotruncal defects broadly.
  • CCHD newborn screening mandates (adopted in most U.S. states and many other countries) function as a population-level secondary-prevention/early-detection public health intervention specifically because TOF is one of the seven core CDC-targeted lesions.

14. Other Species / Natural Disease

Taxonomy and naturally occurring disease

  • Dogs (Canis lupus familiaris, NCBITaxon:9615) — TOF is a recognized, naturally occurring congenital heart defect. OMIA:000994-9615 documents Tetralogy of Fallot in dogs (OMIA).
  • Breed predisposition: Keeshond, English Bulldog, Wire-haired Fox Terrier, and West Highland White Terrier are reportedly overrepresented.
  • Keeshond colony model: Extensive pathologic and genetic studies have been conducted in a dedicated Keeshond research colony with hereditary conotruncal defects. The mode of inheritance in this colony is believed to be autosomal recessive with variable expression, and the defect is described as oligogenic — "The keeshond defect in cardiac conotruncal development is oligogenic" (PMID:15711798). This colony represents one of the best-characterized naturally occurring, heritable large-animal models of human conotruncal CHD and has informed understanding of oligogenic inheritance mechanisms relevant to human non-syndromic TOF.
  • Cats — TOF also occurs, though less commonly documented/characterized than in dogs. A retrospective veterinary case series covering dogs and cats with TOF (31 cases, 2003–2014) characterized epidemiological, clinical, echocardiographic features and survival times (AVMA journal). In one large series of 967 consecutive veterinary CHD cases, TOF prevalence was reported at ~1%.

Veterinary relevance

TOF in dogs and cats presents similarly to the human disease (cyanosis, exercise intolerance, murmur) and carries a guarded prognosis without surgical correction; veterinary management is largely supportive (given more limited surgical infrastructure for complex pediatric-style cardiac surgery in companion animals) compared to the near-universal surgical correction paradigm in human medicine.

Comparative biology

The heritable, oligogenic Keeshond model provides a comparative genetics resource for understanding gene-gene interaction effects on conotruncal septation — directly complementing the human genetic architecture picture (where combinations of NOTCH1/FLT4/NKX2-5/TBX1 and modifier loci, rather than single fully penetrant mutations, appear to determine phenotype in most non-syndromic cases).

Transmission

Not applicable — TOF is a non-infectious congenital developmental malformation, not a transmissible disease, in either humans or other species.

15. Model Organisms

Mouse models (genetic, most extensively used)

  • Tbx1 mutant/knockout mice — recapitulate cardiovascular and glandular defects seen in human DiGeorge/22q11.2 deletion syndrome, including outflow tract lesions such as persistent truncus arteriosus and TOF-like phenotypes; establishes Tbx1 haploinsufficiency as sufficient to cause conotruncal malformation, directly modeling the human 22q11.2DS-TOF association (Circ Res, Tbx1/SHF study).
  • Hey2 mutant mice — develop "tetralogy of Fallot and other congenital heart defects" (PMID:12372254), implicating the Notch-effector Hey2 gene in outflow-tract septation, mechanistically connected to the Notch pathway genes (NOTCH1, JAG1) causally implicated in human TOF.
  • Jag1-deficient mice — show outflow tract abnormalities associated with abnormal ventricular activation and desynchronized contraction (2025 bioRxiv preprint), directly modeling the Notch-ligand mechanism underlying JAG1/Alagille-associated TOF.
  • Nedd4 conditional knockout (Wnt1-Cre;Nedd4^fl/fl) — neural-crest-specific deletion produces outflow tract defects from failed SHF cell addition, and a human NEDD4* variant found in a TOF patient shows impaired function in this model system, linking mouse mechanistic data directly to a human genetic finding.
  • Gata4-hypomorphic/reduced-expression mice — produce double-outlet right ventricle and hypoplastic ventricular myocardium, modeling the GATA4 haploinsufficiency mechanism implicated in a subset of human TOF/conotruncal defects.
  • General mouse conotruncal/SHF/neural-crest lineage-tracing models (Wnt1-Cre, Mef2c-AHF-Cre) are widely used tools for dissecting the SHF and CNCC contributions to outflow tract septation relevant to TOF pathogenesis (Springer chapter, "Molecular Pathways and Animal Models of Tetralogy of Fallot and Double Outlet Right Ventricle").

Phenotype recapitulation and limitations

  • Mouse models robustly recapitulate the anatomic outflow-tract/conotruncal septation defects (VSD, overriding great vessel, RVOT obstruction analogs) and the genetic dosage-sensitivity principle (haploinsufficiency phenotypes for Tbx1, Gata4, Nedd4, Jag1).
  • Limitations: full recapitulation of the exact four-component human TOF phenotype (including the specific degree/pattern of RVOT obstruction and later postnatal RV remodeling/arrhythmia biology) is variable across models; many single-gene mouse knockouts instead produce a broader spectrum of conotruncal defects (persistent truncus arteriosus, double-outlet right ventricle) rather than a TOF-specific phenotype, consistent with the human observation that TOF arises from combinatorial/oligogenic rather than single-gene mechanisms in most non-syndromic cases. This represents a human-model mismatch consideration: single-gene mouse models best capture mechanism/pathway biology rather than the precise clinical anatomic subtype, and postnatal chronic pulmonary-regurgitation/arrhythmia biology (a major driver of human long-term morbidity) is not well modeled by embryonic-lethal or perinatal-lethal knockout lines.

Research applications

  • Dissecting SHF progenitor addition and CNCC migration mechanisms (developmental biology).
  • Testing gene-dosage/haploinsufficiency thresholds relevant to human 22q11.2 deletion-sized regions.
  • Functional validation of candidate human variants (e.g., NEDD4) identified by exome sequencing, bridging human genetics and mechanistic causality.
  • Postnatal RV remodeling/hypoxia and metabolic-stress models (relevant to FOXO1-related postnatal cardiomyocyte vulnerability hypotheses) are an emerging application area.

Resources

Mouse Genome Informatics (MGI) and standard conditional/lineage-tracing Cre driver lines (Wnt1-Cre for neural crest, Mef2c-AHF-Cre for anterior SHF) are the primary community resources underlying this body of work; the large-animal Keeshond dog colony (Section 14) is a complementary heritable natural-disease model resource for oligogenic conotruncal defect genetics.

Summary of Suggested Ontology Terms for KB Curation

(All suggestions should be verified against canonical labels via OAK/appropriate adapters before curation, per standard practice — several IDs above are given with moderate rather than high confidence.)

  • MONDO: MONDO:0008542 (Tetralogy of Fallot)
  • OMIM: #187500
  • Orphanet: ORPHA:3303
  • HPO (phenotypes): HP:0001629 (VSD), HP:0002623 (overriding aorta), HP:0001642 (pulmonic stenosis), HP:0004415 (infundibular pulmonic stenosis), HP:0001714 (RVH), HP:0000961 (cyanosis), HP:0100759 (clubbing), HP:0031264 (heart murmur), HP:0001508 (failure to thrive)
  • GO (biological process): GO:0003151 (outflow tract morphogenesis), GO:0003148 (outflow tract septum morphogenesis), GO:0003208 (cardiac ventricle morphogenesis)
  • CL (cell types): CL:0002079 (cardiac neural crest cell), CL:0000746 (cardiac muscle cell)
  • CHEBI: CHEBI:26536 (retinoic acid), CHEBI:27470 (folic acid)
  • NCIT (treatments): NCIT:C15329 (Surgical Procedure), NCIT:C15240 (Genetic Counseling)
  • Causal/susceptibility genes (HGNC): NOTCH1 (HGNC:7881), FLT4 (HGNC:3767), NKX2-5 (HGNC:2488), JAG1 (HGNC:6188), GATA4 (HGNC:4173), TBX1 (HGNC:11592), TBX5 (HGNC:11602), ZFPM2 (HGNC:19091), PTPN11 (HGNC:9644)

Key Evidence Gaps Identified

  1. Precise TOF-specific male:female sex ratio not robustly quantified in this search.
  2. Germline mosaicism rates for TOF recurrence not well characterized.
  3. Genetic protective variants/alleles specific to TOF are essentially undocumented (in contrast to well-established protective environmental factor — folic acid).
  4. Maternal smoking/obesity effect sizes specific to TOF (as opposed to CHD broadly) were not strongly surfaced.
  5. Mouse models capture pathway mechanism well but rarely recapitulate the precise TOF anatomic subtype or postnatal chronic pulmonary-regurgitation/arrhythmia biology — a human-model-mismatch consideration for any curated model-organism evidence.

Sources